WO1998057966A1 - Novel aryloxy substituted pyrimidine imidazole compounds - Google Patents

Novel aryloxy substituted pyrimidine imidazole compounds Download PDF

Info

Publication number
WO1998057966A1
WO1998057966A1 PCT/US1998/012828 US9812828W WO9857966A1 WO 1998057966 A1 WO1998057966 A1 WO 1998057966A1 US 9812828 W US9812828 W US 9812828W WO 9857966 A1 WO9857966 A1 WO 9857966A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
aryl
hydrogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/012828
Other languages
French (fr)
Inventor
Jerry L. Adams
Dennis Lee
Scott A. Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to JP50486599A priority Critical patent/JP2002505690A/en
Priority to CA002294137A priority patent/CA2294137A1/en
Priority to AU81549/98A priority patent/AU8154998A/en
Priority to EP98931409A priority patent/EP0994870A4/en
Priority to US09/445,652 priority patent/US6610695B1/en
Publication of WO1998057966A1 publication Critical patent/WO1998057966A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Definitions

  • This invention relates to a novel group of aryloxypyrimidine substituted imidazole compounds, processes for the preparation thereof, the use thereof in treating cytokine mediated diseases and pharmaceutical compositions for use in such therapy.
  • Intracellular signal transduction is the means by which cells respond to extracellular stimuli. Regardless of the nature of the cell surface receptor (e. g. protein tyrosine kinase or seven-transmembrane G-protein coupled), protein kinases and phosphatases along with phopholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C. Cell , 80, 179-278 (1995)].
  • protein kinases and phosphatases along with phopholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C. Cell , 80, 179-278 (1995)].
  • Protein kinases can be categorized into five classes with the two major classes being, tyrosine kinases and serine / threonine kinases depending upon whether the enzyme phosphorylates its substrate(s) on specific tyrosine(s) or serine / threonine(s) residues [Hunter, T., Methods in Enzymologv (Protein Kinase Classification) p. 3, Hunter, T.; Sefton, B. M.; eds. vol. 200, Academic Press; San Diego, 1991].
  • kinases For most biological responses, multiple intracellular kinases are involved and an individual kinase can be involved in more than one signaling event. These kinases are often cytosolic and can translocate to the nucleus or the ribosomes where they can affect transcriptional and translational events, respectively. The involvement of kinases in transcriptional control is presently much better understood than their effect on translation as illustrated by the studies on growth factor induced signal transduction involving MAP/ERK kinase [Marshall, C. J. Cell . 80, 179 (1995); Herskowitz, I. Cell . 80, 187 (1995); Hunter, T. Cell . 80, 225 (1995); Seger, R., and Krebs, E. G. FASEB J., 726-735 (1995)].
  • cytokines e.g., IL-1 and TNF
  • mediators of inflammation e.g., COX-2, and iNOS
  • LPS bacterial lippopolysaccharide
  • p38 identified murine p38 as a kinase which is tyrosine phosphorylated in response to LPS.
  • Definitive proof of the involvement of the p38 kinase in LPS-stimulated signal transduction pathway leading to the initiation of proinflammatory cytokine biosynthesis was provided by the independent discovery of p38 kinase by Lee [Lee, et al., Nature. 372, 739(1994)] as the molecular target for a novel class of anti-inflammatory agents.
  • the discovery of p38 (termed by Lee as CSBP 1 and 2) provided a mechanism of action of a class of anti- inflammatory compounds for which SK&F 86002 was the prototypic example.
  • CSBP/p38 is a one of several kinases involved in a stress-response signal transduction pathway which is parallel to and largely independent of the analogous mitogen-activated protein kinase (MAP) kinase cascade ( Figure 1).
  • Stress signals including LPS, pro-inflammatory cytokines, oxidants, UV light and osmotic stress, activate kinases upstream from CSBP/p38 which in turn phosphorylate CSBP/p38 at threonine 180 and tyrosine 182 resulting in CSBP/p38 activation.
  • MAPKAP kinase-2 and MAPKAP kinase-3 have been identified as downstream substrates of CSBP/p38 which in turn phosphorylate heat shock protein Hsp 27 ( Figure 2). It is not yet known whether MAPKAP-2, MAPKAP-3, Mnkl or Mnk2 are involved in cytokine biosynthesis or alternatively that inhibitors of CSBP/p38 kinase might regulate cytokine biosynthesis by blocking a yet unidentified substrate downstream from CSBP/p38 [Cohen, P. Trends Cell Biol.. 353-361(1997)].
  • CSBP/p38 kinase inhibitors (SK&F 86002 and SB 203580) also decrease the synthesis of a wide variety of pro-inflammatory proteins including, IL-6, IL-8, GM-CSF and COX-2.
  • Inhibitors of CSBP/p38 kinase have also been shown to suppress the TNF- induced expression of VCAM-1 on endothelial cells, the TNF-induced phosphorylation and activation of cytosolic PLA2 and the IL-1 -stimulated synthesis of collagenase and stromelysin.
  • Interleukin- 1 IL-1
  • Tumor Necrosis Factor TNF
  • IL-1 Tumor Necrosis Factor
  • monocytes or macrophages IL-1
  • IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)].
  • the myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.
  • TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, reperfusion injury, graft vs.
  • allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
  • AIDS cachexia secondary to infection or malignancy
  • cachexia secondary to acquired immune deficiency syndrome
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis or pyresis.
  • Interleukin-8 is a chemotactic factor produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. Its production from endothelial cells is induced by IL- 1 , TNF, or lipopolysachharide (LPS). IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes, and basophils. In addition it induces histamine release from basophils from both normal and atopic individuals as well as lysozomal enzyme release and respiratory burst from neutrophils.
  • IL-8 Interleukin-8
  • IL-8 has also been shown to increase the surface expression of Mac- 1 (CDl lb/CD 18) on neutrophils without de novo protein synthesis, this may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many diseases are characterized by massive neutrophil infiltration. Conditions associated with an increased in IL-8 production (which is responsible for chemotaxis of neutrophil into the inflammatory site) would benefit by compounds which are suppressive of IL-8 production.
  • IL-1 and TNF affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
  • CSBP/p38 Inhibition of signal transduction via CSBP/p38, which in addition to IL-1, TNF and IL-8 described above is also required for the synthesis and/or action of several additional pro-inflammatory proteins (i.e., IL-6, GM-CSF, COX-2, collagenase and stromelysin), is expected to be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. This expectation is supported by the potent and diverse anti-inflammatory activities described for CSBP/p38 kinase inhibitors [Badger, et al, J. Pharm. Exp. Thera. 279 (3): 1453- 1461.(1996); Griswold, et al, Pharmacol. Comm. 7, 323-229 (1996)].
  • This invention relates to the novel compounds of Formula (I) and pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier.
  • This invention relates to a method of propylaxis, or the treatment of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective prophylatic or treatment amount of a compound of Formula (I).
  • This invention also relates to a method of inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • This invention more specifically relates to a method of inhibiting the production of IL- 1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • This invention more specifically relates to a method of inhibiting the production of IL-6 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • This invention more specifically relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • This invention more specifically relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • Ri is 4-pyrimidinyl ring which ring is substituted by Y, or NHR a , and is optionally substituted independently one to three times with Y, NHR a , optionally substituted C1-.4 alkyl, halogen, hydroxyl, optionally substituted Ci-4 alkoxy, optionally substituted C1-.4 alkylthio, optionally substituted C1-.4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(R ⁇ o)C(O)Rb, N(R ⁇ o)S(O)2Rd > or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or
  • Y is X ⁇ -R a ;
  • X ⁇ is sulfur or oxygen;
  • R a is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylCi-6alkyl, wherein each of these moieties may be optionally substituted;
  • Rb is hydrogen, Ci-6 alkyl, C3-.7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl;
  • Rd is C ⁇ _6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylC ⁇ -4 alkyl;
  • R2 is hydrogen, Ci-io alkyl, halo-substit
  • n is 0 or an integer from 1 to 10; n' is an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; t is a number having a value of 1, 2 or 3; v is 0, or an integer having a value of 1 or 2;
  • Q is an aryl or heteroaryl group
  • Z is oxygen or sulfur
  • Yl is independently selected from hydrogen, C1-.5 alkyl, halo-substituted C1-.5 alkyl, halogen, or (CR ⁇ oR2 ⁇ )nY2;
  • Y2 is OR 8 , NO2, S(O)m ,, Rl l, SRs, S(O) m "OR 8 , S(O) m NRsR9, NR 8 R9,
  • 4-phenyl, 4-naphth-l-yl or 5-naphth-2-yl substituent is halo,nitro, cyano, C(Z)NR 7 Ri7, C(Z)OR 3, (CRioR2 ⁇ )vCOR 36 , SR5, SOR5, OR36, halo- substituted-Ci-4 alkyl, C1-.4 alkyl, ZC(Z)R36, NR ⁇ oC(Z)R23, or (CRioR2 ⁇ )vNRioR20 and which, for other positions of substitution, is halo, nitro, cyano, C(Z)NRi6R26, C(Z)OR 8 , (CR ⁇ oR2 ⁇ )m"COR 8 , S(O) m R 8 , OR 8 , halo-substituted-Ci-4 alkyl, Ci_4 alkyl, CR ⁇ oR2 ⁇ )m"NRl ⁇ C(Z)R 8 , NRioS(
  • R 8 is hydrogen, heterocyclyl, heterocyclylalkyl or Ri 1;
  • R9 is hydrogen, Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl or R 8 and R9 may together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12;
  • Rio and R20 is each independently selected from hydrogen or C1-.4 alkyl;
  • Rl 1 is Ci-io alkyl, halo- substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-.7 cycloalkyl, C5_7 cycloalkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;
  • Rl2 is hydrogen, -C(Z)Ri3 or optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted arylCi-4 alkyl, or S(O)2R25»
  • R13 is hydrogen, Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclylCi-io alkyl, aryl, arylCi-10 alkyl, heteroaryl or heteroaryl Ci-io alkyl, wherein all of these moieties may be optionally substituted;
  • Rl4 and R24 is each independently selected from hydrogen, alkyl,
  • Rl 8 and R19 is each independently selected from hydrogen, C ⁇ _4 alkyl, substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl or together denote a oxygen or sulfur;
  • R21 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, aryl Ci-4 alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, aroyl, or Ci-io alkanoyl ;
  • R23 is C 1-4 alkyl, halo-substituted-Ci-4 alkyl, or C3-5 cycloalkyl;
  • R25 is C i-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, arylalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroarylalkyl;
  • R27 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl, or aryl;
  • R2 8 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety, all of which may be optionally substituted;
  • R36 is hydrogen or R23; or a pharmaceutically acceptable salt thereof.
  • novel compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of cytokine inhibition or production.
  • cytokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section, but in particular viral infections.
  • viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retro viral infections.
  • lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodefici
  • Ri is a 4-pyrimidinyl ring, which ring is substituted by Y, or NHR a .
  • the ring may also be optionally substituted independently one to three times with Y, NHR a , optionally substituted Ci-4 alkyl, halogen, hydroxyl, optionally substituted Ci-4 alkoxy, optionally substituted Ci-4 alkylthio, optionally substituted Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(R ⁇ o)C(O)Rb, N(R ⁇ o)S(O)2Rd, or an
  • N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15.
  • the ring is substituted by Y.
  • Y is X ⁇ -R a ; and Xi is sulfur or oxygen, preferably oxygen.
  • R a is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylC 1 -6 alkyl, heteroaryl, or heteroarylCi-6alkyl, wherein each of these moieties may be optionally substituted.
  • R a is C ⁇ _6alkyl, aryl, or arylCi-6alkyl. More preferably aryl, or arylCi-6alkyl.
  • Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylC ⁇ _4alkyl, heterocyclyl, or heterocyclylC 1.4 alkyl; wherein each of these moieties may be optionally substituted.
  • Rd is Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylC 1 -.4 alkyl; wherein each of these moieties may be optionally substituted.
  • a preferred ring placement on the 4-pyrimidinyl ring is at the 2-position, such as in 2-methoxy-pyrimidine or 2-phenxoy-pyrimidine.
  • R2 is hydrogen, Ci-io alkyl, halo-substituted C ⁇ _ ⁇ o alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-.7 cycloalkylCi-ioalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, heterocyclyl, heterocyclylC 1-10 alkyl, (CR ⁇ oR28)n OR12, (CR ⁇ oR28)n , ORi3, (CRioR28)n'
  • R2 is hydrogen, an optionally substituted heterocyclyl ring, and optionally substituted heterocyclylC ⁇ _ 10 alkyl, an optionally substituted C ⁇ io alkyl, an optionally substituted C3-7cycloalkyl, an optionally substituted C3_7cycloalkyl C ⁇ _ ⁇ 0 alkyl, (CR ⁇ oR28)n OR 12, (CR ⁇ oR28)n'C(Z)ORi3 group, (CR ⁇ 0 R28)n'NR 8 R 9 , (CRioR28)n'NHS(O) 2 R25, (CRl ⁇ R28)n'S(O) m R25.
  • R2 is hydrogen, (CR ⁇ oR28)n OR12, an optionally substituted Ci-io alkyl, an optionally substituted heterocyclyl ring, an optionally substituted heterocyclylC l- 10 alkyl, an optionally substituted aryl, an optionally substituted Ci-io alkyl, an optionally substituted C3-7cycloalkyl, an optionally substituted C3-7cycloalkyl Ci-io alkyl, (CR ⁇ oR2 ⁇ )n'NR8R9, or (CR ⁇ oR2 ⁇ )n'C(Z)ORi3 group.
  • R2 is hydrogen, an optionally substituted heterocyclyl ring, an optionally substituted heterocyclylC ⁇ _ 10 alkyl, an optionally substituted C3-7cycloalkyl, or an optionally substituted C3_7cycloalkyl Ci-io alkyl.
  • R2 is an optionally substituted heterocyclyl
  • the ring is preferably a morpholino, pyrrolidinyl, or a piperidinyl group.
  • the substituents may be directly attached to the free nitrogen, such as in the piperidinyl group or pyrrole ring, or on the ring itself.
  • the ring is a piperidine or pyrrole, more preferably piperidine.
  • heterocyclyl ring may be optionally substituted one to four times independently by halogen; Cj-4 alkyl; aryl, such as phenyl; aryl alkyl, such as benzyl - wherein the aryl or aryl alkyl moieties themselves may be optionally substituted (as in the definition section below); C(O)ORi3, such as the C(O)C ⁇ _4 alkyl or C(O)OH moieties; C(O)H; C(O)Ci-4 alkyl, hydroxy substituted Ci-4 alkyl, Ci-4 alkoxy, S(O) m Ci-4 alkyl (wherein m is 0, 1, or 2), NR10R2O (wherein Rio and R20 are independently hydrogen or C ⁇ _4alkyl).
  • the ring is a piperidine
  • the ring is attached to the imidazole at the 4-position, and the substituents are directly on the available nitrogen, i.e. a 1 -Formyl-4-piperidine, 1 -benzyl-4-piperidine, 1 -methyl-4-piperidine, l-ethoxycarbonyl-4-piperidine.
  • the ring is substituted by an alkyl group and the ring is attached in the 4-position, it is preferably substituted in the 2 or 6 position or both, such as 2,2,6,6-tetramethyl-4-piperidine.
  • the ring is a pyrrole
  • the ring is attached to the imidazole at the 3-position, and the substituents are also directly on the available nitrogen.
  • the ring is preferably a morpholino, pyrrolidinyl, or a piperidinyl group.
  • this alkyl moiety is from 1 to 4, more preferably 3 or 4, and most preferably 3, such as in a propyl group.
  • Preferred heterocyclic alkyl groups include but are not limited to, morpholino ethyl, morpholino propyl, pyrrollidinyl propyl, and piperidinyl propyl moieties.
  • the heterocyclic ring herein is also optionally substituted in a similar manner to that indicated above for the direct attachment of the heterocyclyl.
  • the cycloalkyl group is preferably a C5 to C6 ring.
  • the C3-7cycloalkyl, and C3-7cycloalkyl Ci-io alkyl ring may be optionally substituted one or more times independently by halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; Ci-io alkoxy, such as methoxy or ethoxy; S(O) m alkyl, wherein m is 0, 1, or 2, such as methyl thio, methylsulfinyl or methyl sulfonyl; amino, mono & di-substituted amino, such as in the NR7R17 group; or where the R7R17 may cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally includes an additional heteroatom selected from O/N/S; Ci-io alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; halosubstituted alkyl, such as
  • R 8 and R9 are each independently selected from hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl or an optionally substituted aryl- Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12. It is recognized that in some instances this can yield the same moiety as a heterocyclic Ci-io alkyl moiety noted above which is also a suitable R2 variable.
  • R 8 and R9 are independently hydrogen, Ci-4 alkyl, preferably methyl, or benzyl.
  • n term is preferably 1 to 4, more preferably 3 or 4, and most preferably 3, such as in a propyl group.
  • Preferred groups include, but are not limited to, aminopropyl, (N-methyl-N-benzyl)aminopropyl, (N- Phenyl-methyl)amino-l -propyl, or diethylamino propyl.
  • R13 is suitably hydrogen, C ⁇ . 4 alkyl, especially methyl.
  • the n' term is preferably 1 to 4, more preferably 2 or 3, such as in an ethyl or propyl group.
  • Preferred groups include, but are not limited to, carboxymethyl-1 -butyl, carboxy-1 -propyl, or 2-acetoxy ethyl.
  • R2 is a (CR ⁇ oR28)n'S(O) m
  • R25 group m is 0, 1, or 2
  • R ⁇ 8 is preferably aryl, especially phenyl, or Ci-io alkyl, especially methyl.
  • the n term is preferably 1 to 4, more preferably 2 or 3, such as in an ethyl or propyl group.
  • R ⁇ is suitably hydrogen, aryl, especially phenyl, or Ci-io alkyl, especially methyl or ethyl.
  • n term is preferably 1 to 4, more preferably 2 or 3, such as in an ethyl or propyl group.
  • R25 is suitably alkyl, especially methyl.
  • the n term is preferably 1 to 4, more preferably 2 or 3, such as in an ethyl or propyl group.
  • R2 is a optionally substituted aryl
  • the aryl is preferably phenyl.
  • the aryl ring may be optionally substituted one or more times, preferably by one or two substituents, independently selected from Ci-4 alkyl, halogen, especially fluoro or chloro, (CRioR28)tORl3, (wherein t is 0, or an integer of 1 to 4), (CR ⁇ o 28)t RioR20- especially amino or mono- or di-alkylamino (CR ⁇ oR28)tS(O) m R25, wherein m is 0, 1 or 2 ; SH, (CRioR2 ⁇ )nNR 8 R9, NR ⁇ oC(Z)R 8 (such NHCO(Ci-io alkyl)), or NR ⁇ oS(O) m R25 (such as NHSO2(Ci-io alkyl)).
  • the phenyl is substituted in the 3 or 4- position by (CR ⁇ oR28)tS(O
  • R2 is an optionally substituted heteroaryl or heteroarylalkyl group
  • the ring may be optionally substituted one or more times, preferably by one or two substituents, independently selected from one or more times, by Ci-4 alkyl, halogen, especially fluoro or chloro, (CR ⁇ oR28)tORl3, (CR ⁇ oR28)tNRi ⁇ R20 . especially amino or mono- or di-alkylamino, (CR ⁇ oR28)tS(O) m R25 > wherein m is 0, 1 or 2 ;
  • NR ⁇ oS(O) m R25 (such as NHS ⁇ 2(C ⁇ _ ⁇ o alkyl)); t is 0, or an integer of 1 to 4.
  • n is preferably at least 2 which will allow for the synthesis of stable compounds.
  • R2 is hydrogen, Ci-4 alkyl (branched and unbranched), a methylthio propyl, a methylsulfinyl propyl, an amino propyl, N-methyl-N- benzylamino propyl group, diethylamino propyl, cyclopropyl methyl, morpholinyl butyl, morpholinyl propyl, a morpholinyl ethyl, a piperidine or a substituted piperidine.
  • R2 is isopropyl; butyl; t-butyl; n-propyl; methylthiopropyl or methylsulfinyl propyl; morpholino propyl; morpholinyl butyl; phenyl substituted by halogen, thioalkyl or sulfinyl alkyl such as a methylthio, methylsulfinyl or methylsulfonyl moiety; piperidinyl; l-Formyl-4-piperidine; 1 -benzyl -4-piperidine; l-methyl-4-piperidine, or a l-ethoxycarbonyl-4-piperidine.
  • R3 is Q-(Yl)t, and Q is an optionally substituted aryl or heteroaryl moiety.
  • Q is an aryl
  • it is phenyl
  • Q is a heteroaryl
  • preferred rings include thienyl, pyrrole, pyridine, or pyrimidine.
  • Q is a substituted phenyl.
  • t is 1 and R3 is mono-substituted phenyl, the substituent is located at the 4-position of the ring.
  • t is a number having a value of 1 to 3, preferably t is 1 or 2.
  • Yl is independently selected from hydrogen, C1-.5 alkyl, halo-substituted Ci-5 alkyl, halogen, or (CR ⁇ oR2 ⁇ )nY2.
  • Y2 is OR 8 , NO2, S(O) m “Rl l, SR 8 , S(O) m “OR 8 , S(O) m NR 8 R9,
  • NR 8 R 9 O(CR ⁇ 0 R20)n'NR 8 R9.
  • substituents include halogen, Ci-5 alkyl and (CR ⁇ oR2 ⁇ )nY2 •
  • a preferred monosubstituent for Yi when the aryl or heteroaryl group Q is mono-substituted include (CR ⁇ oR2 ⁇ )nY2 wherein: n is preferably 0, 1, 2 or 3, more preferably 0 or 1; and Y2 is OR 8 , especially where R 8 is hydrogen or Ci-io alkyl; NO2; S(O) m 'R ⁇ 1, especially where Ri 1 is Ci-io alkyl; SR 8 , especially where R 8 is Ci-io alkyl; S(O) m NR 8 R9, especially where R 8 and R9 is each hydrogen or Ci-io alkyl or R 8 and R9 together with the nitrogen to which they are attached form a 5 to 7 membered ring which optionally includes another heteroatom selected from oxygen, sulfur or NR12 and m is 2; n' is 1 to 10; -NR 8 R9 , especially where R 8 and R9 is each hydrogen, methyl or benzyl or R 8 and R9 together with the nitrogen to
  • substituents include those hereinbefore noted for use when Q is mono-substituted and, as further substituent(s), halogen and Ci-io alkyl.
  • R3 is phenyl substituted with two or three substituents
  • the alkyl moieties preferably have from one to three carbons, more preferably one.
  • Preferred phenyl ring positions for two substituents are the 3- and 4-positions and, for three substituents, the 3-, 4- and 5- positions.
  • the substituent at the 3- and 5-positions is preferably C ⁇ _2 alkyl, such as methyl, or halogen, such as bromo, fluoro or chloro, while the substituent at the 4-position is preferably hydroxyl.
  • Yl is (CR ⁇ oR20) n Y2, and n is 0 or 1; Y2 is OH, or S(O) m 'Ri 1, especially where Rn is Ci-io alkyl; SR 8 , especially where R 8 is C ⁇ _ 10 alkyl; NR 8 R9, especially where R 8 and R9 is hydrogen, alkyl, aryl alkyl, or aryl or R 8 and R9 together with the nitrogen to which they are attached form a pyrrolidinyl, piperidinyl or morpholinyl ring, more prefereably the R 8 and R9 terms in the NR 8 R9 moiety are hydrogen, methyl or benzyl; CO2R 8 , especially where R 8 is hydrogen or Ci-io alkyl; S(O) m 'NR 8 R9, especially where R 8 and R9 is each hydrogen or C ⁇ _ ⁇ o alkyl; NRioS(O) m Rl 1, especially where Rio is hydrogen and Ri 1
  • Yl is methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, N,N-dimethylaminomethyl, N-benzyl-N-methylaminomethyl, N-morpholinomethyl, methanesulfonamido, sulphonamidomethyl, 5-methyl-4,5- dihydro-l,2,4-oxadiazol-3-yl or 5,5-dimethyl-4,5-dihydro-l,2,4-oxadiazol-3-yl.
  • the unsaturated linkage i.e., the vinylene or acetylene linkage is preferably not directly attached to the nitrogen, oxygen or sulfur moieties, for instance in Y2 as C(Z)NR 8 OR9, NR ⁇ oC(Z)NR 8 R9, or OR 8 .
  • halogen such as fluorine, chlorine, bromine or iodine
  • hydroxy hydroxy substituted Ci-ioalkyl
  • Ci-io alkoxy such as methoxy or ethoxy
  • halosubstituted Ci-io alkoxy S(O)m alkyl, wherein m is 0, 1 or 2, such as methyl thio, methylsulfinyl or methyl sulfonyl
  • amino, mono & di-substituted amino such as in the NR7R17 group; or where the R7R17 may together with the nitrogen to which they are attached cyclize to form a 5 to 7 membered ring which optionally includes an additional heteroatom selected from O/N/S; C ⁇ _ ⁇ o alkyl, cycloalkyl, or cycloalkyl alkyl group, such as methyl, ethyl, propyl, isoprop
  • Ci-io alkyl such CF3
  • an optionally substituted aryl such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, wherein these aryl moieties may also be substituted one to two times by halogen, hydroxy, hydroxy substituted alkyl, Ci-io alkoxy, S(O) m alkyl, amino, mono & di-substituted amino, such as in the NR7R17 group, Ci-io alkyl, or CF3.
  • substitutions for R4 when it is a 4-phenyl, 4-naphth-l-yl or 5- naphth-2-yl moiety are one or two substituents each independently selected from halogen, SR5, SOR5, OR36, or (CRio 2 ⁇ )mNRl ⁇ R20- and for other positions of substitution on these rings preferred substitution is halogen, S(O) m R 8 , OR 8 , (CRioR20)mNRl6R26, NR ⁇ oC(Z)R 8 and NR ⁇ oS(O) m R ⁇ 1.
  • substituents for the 4-position in phenyl and naphth-1-yl and on the 5 -position in naphth-2-yl include halogen, especially fluoro and chloro, and SR5 and SOR5 wherein R5 is preferably a Ci-2 alkyl, more preferably methyl; of which fluoro is especially preferred.
  • Preferred substituents for the 3-position in phenyl and naphth- 1-yl include: halogen, especially chloro; OR 8 , especially Ci-4 alkoxy; amino; NRIQC(Z)R 8 , especially NHCO(C ⁇ _ ⁇ o alkyl); and NR ⁇ oS(O) m Rl l, especially NHS ⁇ 2(C ⁇ _ ⁇ o alkyl).
  • the R4 moiety is an unsubstituted or substituted phenyl moiety. More preferably, R4 is phenyl or phenyl substituted at the 4-position with fluoro and/or substituted at the 3-position with fluoro, chloro, Ci-4 alkoxy, methanesulfonamido or acetamido.
  • a preferred grouping of Formula (I) are those compounds wherein Rj is a 4- pyrimidiny ring, which ring is substituted by Y, and R2 is hydrogen, an optionally substituted C ⁇ _ ⁇ o alkyl, optionally substituted C3-7cycloalkyl, or an optionally substituted C3-7cycloalkyl C -io alkyl, an optionally substituted aryl, an optionally substituted heterocyclic alkyl, an optionally substituted heterocyclic, optionally substituted heteroaryl or heteroarylalkyl, (CR ⁇ oR28)n'ORl3 ?
  • R2 is a Ci-4 alkyl (branched and unbranched), such as isopropyl, butyl, t-butyl, n-propyl, a methylthio propyl, a methylsulfinyl propyl, an amino propyl, N-methyl-N-benzylamino propyl group, (phenylmethyl)amino- 1 -propyl, diethylamino propyl, cyclopropyl methyl, morpholinyl butyl, morpholinyl propyl, morpholinyl ethyl, l-Formyl-4-piperidinyl, 1 -benzyl-4-piperidinyl, 1 -methyl-4-piperidinyl, 1 -ethoxycarbonyl-4-piperidinyl,
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
  • pharmaceutically acceptable salts of compounds of formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent Yi in R3 comprises a carboxy group.
  • Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quarternary ammonium cations.
  • halo all halogens, that is chloro, fluoro, bromo and iodo; • "C ⁇ _ oalkyl” or “alkyl” - both straight and branched chain radicals of 1 to
  • cycloalkyl is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • cycloalkenyl is used herein to mean cyclic radicals, preferably of 5 to 8 carbons, which have at least one bond including but not limited to cyclopentenyl, cyclohexenyl, and the like.
  • heteroaryl - phenyl and naphthyl
  • heteroaryl (on its own or in any combination, such as “heteroaryloxy") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole; • "heterocyclic” (on its own or in any combination, such as
  • heterocyclylalkyl a saturated or wholly or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, imidazolidine or pyrazolidine; • "aroyl” - a C(O)Ar, wherein Ar is as phenyl, naphthyl, or aryl alkyl derivative such as defined above, such group include but are note limited to benzyl and phenethyl;
  • alkanoyl - a C(O)Ci-ioalkyl wherein the alkyl is as defined above;
  • aralkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean an aryl, heteroaryl or heterocyclic moiety as respectively defined above said group connected to C ⁇ _6 alkyl group as also defined above unless otherwise indicated.
  • the compounds of the present invention may exist as stereoisomers, regioisomers, or diastereiomers. These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are included within the scope of the present invention.
  • the compounds of formula (I) are named by their position corresponding to:
  • Exemplified compounds of formula (I) include: 2-(4-Methylthiophenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)imidazole; 2-(4-Methylsulfinylphenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidiny l)imidazole ; 2-[(4-N,N-Dimethyl)aminomethylphenyl]-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole; 2-[(4-N,N-Dimethyl)aminomethylphenyl]-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyridminyl)imidazole;
  • a benzoic acid is treated with N-methoxymethylamine, EDC and 1-hydroxy- benzotriazole to give N-methoxy,N-methyl-4-fluorobenzamide 4.
  • Deprotonation of 4-methyl-2-thiomethylpyrimidine with a strong base such as lithium diisopropylamide followed by treatment with 4 yields an intermediate ketone, which upon treatment with an oxidant such as m-CPBA in an organic solvent such as methylene chloride followed by addition of an alkoxide or phenoxide yields alkoxy - or phenoxy-pyrimidine 5.
  • This ketone may be treated with sodium nitrite and aqueous HCl to give keto-oxime 6.
  • keto-oxime is condensed with a substituted aromatic aldehyde and ammonium acetate in acetic acid to give imidazole-N-oxide 7.
  • N-oxide Treatment of the N-oxide with triethyl phosphite in an organic solvent such as
  • N,N-dimethylacetamide or dimethylformamide at 100 C yields 8.
  • R2 contains a thioether
  • treatment with an oxidant such as Oxone in an organic solvent such as methylene chloride yields the sulfoxide and sulfone 9.
  • a primary amine R3NH2 is treated (in Scheme II below) with 4- bromomethyl-2-methylthio-pyrimidine, 10 (prepared according to the procedure by Lucjan, S. et al, J. Org. Chem. 56, 5610, 1991), to give 11 which is then converted to the amide 12 by standard techniques.
  • Oxidation and displacement of the methylthio group as described above for compound 4 affords the alkoxypyrimidine 14.
  • NRioSO2 8 from NHR10 by treatment with ClSO2R 8 by heating in pyridine;
  • NR ⁇ oC(S)R 8 from NR ⁇ oC(O)R 8 by treatment with Lawesson's reagent [2,4-bis(4- methoxyphenyl)-l,3,2,4-dithiadiphosphetane-2,4-disulfide]; NR10SO2CF3 from NHR6 with triflic anhydride and base; NR ⁇ oC(O)-C(O)-OR 8 from NHR10 with, e.g. methyloxalyl chloride and a base such as triethylamine; NR ⁇ oC(O)-C(O)-NR R9 from
  • R6 is Ci-4 alkyl, halo-substituted-Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or C3-5 cycloalkyl.
  • Compounds of Formula (I) in which R2 is hydrogen may be readily converted into further compounds of formula (I) in which R2 is other than hydrogen, for instance alkyl, by conventional procedures such as alkylation or acylation followed by reduction. Such methods are in general relatively inefficient as they lack regiospecificty and the desired N-l product has to be separated from the mixture of N-l and N-3 products, for instance by chromatography or fractional crystallisation.
  • Suitable protecting groups for use with hydroxyl groups and the imidazole nitrogen are well known in the art and described in many references, for instance, Protecting Groups in Organic Synthesis, Greene T W, Wiley-Interscience, New York, 1981.
  • hydroxyl protecting groups include silyl ethers, such as t-butyldimethyl or t-butyldiphenyl, and alkyl ethers, such as methyl connected by an alkyl chain of variable link, (CR ⁇ oR2 ⁇ )n-
  • alkyl ethers such as methyl connected by an alkyl chain of variable link, (CR ⁇ oR2 ⁇ )n-
  • imidazole nitrogen protecting groups include tetrahydropyranyl.
  • the compounds of Formula (I), where R4 may be an alkylsulfinyl, arylsulfinyl, alkylsulfonyl, or arylsulfonyl are prodrugs which are reductively converted in vivo to the corresponding alkylthio or arylthio form.
  • Pharmaceutically acid addition salts of compounds of formula (I) may be obtained in known manner, for example by treatment thereof with an appropriate amount of acid in the presence of a suitable solvent.
  • the compounds of Formula (I) or a pharmaceutically acceptable salt thereof can be used in the manufacutre of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated cytokine producution by such mammal's cell, such as but not limited to monocytes and/or macrophages.
  • Compounds of formula (I) are capable of inhibiting proinflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF and are therefore of use in therapy.
  • IL- 1, IL-6, IL-8 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte-derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions.
  • the inhibition of these pro-inflammatory cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
  • Compounds of Formula (I) are capable of inhibiting inducible proinflammatory proteins, such as COX-2, also referred to by many other names such as prostaglandin endoperoxide synthase-2 (PGHS-2) and are therefore of use in therapy.
  • COX-2 also referred to by many other names
  • PGHS-2 prostaglandin endoperoxide synthase-2
  • These proinflammatory lipid mediators of the cyclooxygenase (CO) pathway are produced by the inducible COX-2 enzyme.
  • Regulation, therefore of COX-2 which is responsible for the these products derived from arachidonic acid, such as prostaglandins affect a wide variety of cells and tissues are important and critical inflammatory mediators of a wide variety of disease states and conditions. Expression of COX-1 is not effected by compounds of Formula (I).
  • This selective inhibition of COX-2 may alleviate or spare ulcerogenic liability associated with inhibition of COX- 1 thereby inhibiting prostoglandins essential for cytoprotective effects.
  • inhibition of these proinflammatory mediators is of benefit in controlling, reducing and alleviating many of these disease states.
  • these inflammatory mediators in particular prostaglandins, have been implicated in pain, such as in the sensitization of pain receptors, or edema.
  • This aspect of pain management therefore includes treatment of neuromuscular pain, headache, cancer pain, and arthritis pain.
  • Compounds of Formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme.
  • the present invention provides a method of inhibiting the synthesis of COX-2 which comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention also provides for a method of prophylaxis treatment in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme.
  • the present invention provides a method of treating a cytokine- mediated disease which comprises administering an effective cytokine-interferring amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • compounds of formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy of any disease state in a human, or other mammal, which is exacerbated by or caused by excessive or unregulated IL-1, IL-6, IL-8 or TNF production by such mammal's cell, such as, but not limited to, monocytes and or macrophages.
  • this invention relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • IL- 1 production is implicated in exacerbating and/or causing the disease.
  • diseases states include rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resorption, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis. Recent evidence also links IL-1 activity to diabetes, pancreatic ⁇ cells and Alzheimer's disease.
  • this invention relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof
  • TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, such as osteoporosis, reperfusion injury, graft vs.
  • diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis,
  • allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis and pyresis.
  • AIDS cachexia secondary to infection or malignancy
  • AIDS cachexia secondary to acquired immune deficiency syndrome
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis ulcerative colitis
  • viruses of formula (I) are also useful in the treatment of viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo.
  • the viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibiting-compounds of formula (1).
  • viruses include, but are not limited to HIV-1, HIV-2 and HIV- 3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses, such as but not limited to, Herpes Zoster and Herpes Simplex.
  • this invention relates to a method of treating a mammal, preferably a human, afflicted with a human immunodeficiency virus (HIV) which comprises administering to such mammal an effective TNF inhibiting amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • a mammal preferably a human, afflicted with a human immunodeficiency virus (HIV)
  • HAV human immunodeficiency virus
  • TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections.
  • viruses include, but are not limited to, the lentivirus infections such as equine infectious anaemia virus, caprine arthritis virus, visna virus, or the maedi virus, or the retroviruses, such as feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus.
  • the compounds of formula (I) may also be used topically in the treatment or prophylaxis of topical disease states mediated by or exacerbated by excessive cytokine production, such as by IL-1 or TNF respectively, such as inflamed joints, eczema, psoriasis and other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
  • cytokine production such as by IL-1 or TNF respectively, such as inflamed joints, eczema, psoriasis and other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
  • this invention relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • IL-8 IL-8
  • IL-1, TNF, and IL-6 inflammatory cytokines
  • IL-8 has the unique property of promoting neutrophil chemotaxis and activation. Therefore, the inhibition of IL-8 production would lead to a direct reduction in the neutophil infiltration.
  • the compounds of formula (I) are administered in an amount sufficient to inhibit cytokine, in particular IL-1, IL-8 or TNF, production such that it is regulated down to normal levels, or in some case to subnormal levels, so as to ameliorate or prevent the disease state.
  • Abnormal levels of IL-1, IL-8 or TNF constitute: (i) levels of free (not cell bound) IL-1, IL-8 or TNF greater than or equal to 1 picogram per ml; (ii) any cell associated IL-1, IL-8 or TNF; or (iii) the presence of IL-1, IL-8 or TNF mRNA above basal levels in cells or tissues in which IL-1, IL-8 or TNF, respectively, is produced.
  • the compounds of formula (I) are inhibitors of cytokines, specifically IL-1, IL-8 and TNF is based upon the effects of the compounds of formulas (I) on the production of the IL-1, IL-8 and TNF in in vitro assays which are described herein.
  • the term "inhibiting the production of IL-1 (IL-8 or TNF)” refers to: a) a decrease of excessive in vivo levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal or sub-normal levels by inhibition of the in vivo release of the cytokine by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the genomic level, of excessive in vivo levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal or sub-normal levels; c) a down regulation, by inhibition of the direct synthesis of the cytokine (IL- 1, IL-8 or TNF) as a postranslational event; or d) a down regulation, at the translational level, of excessive in vivo levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal or sub-normal levels.
  • TNF mediated disease or disease state refers to any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8.
  • cytokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response.
  • a cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them.
  • a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte.
  • Lymphokines are generally referred to as being produced by lymphoctye cells.
  • cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor- alpha (TNF- a) and Tumor Necrosis Factor beta (TNF- ⁇ ).
  • cytokine interfering or "cytokine suppresive amount” refers to an effective amount of a compound of formula (I) which will cause a decrease in the in vivo levels of the cytokine to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production.
  • the cytokine referred to in the phrase "inhibition of a cytokine, for use in the treatment of a HIV-infected human” is a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HIV gene expression and/or replication and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration.
  • TNF- ⁇ also known as lymphotoxin
  • TNF-a also known as cachectin
  • CSBP MAP kinase
  • cytokine biosynthesis inhibitors of the present invention, compounds of Formula (I), have been determined to be potent and selective inhibitors of CSBP/p38/RK kinase activity. These inhibitors are of aid in determining the signaling pathways involvement in inflammatory responses.
  • a definitive signal transduction pathway can be prescribed to the action of lipopolysaccharide in cytokine production in macrophages.
  • treatment of stroke, neurotrauma, cardiac and renal reperfusion injury, congestive heart failure, thrombosis, chronic renal failure, glomerulonephritis, angiogenesis & related processes such as cancer, diabetes and pancreatic ⁇ cells diseases, multiple sclerosis, muscle degeneration, eczema, psoriasis, sunburn, and conjunctivitis are also included.
  • the cytokine inhibitors were subsequently tested in a number of animal models for anti-inflammatory activity. Model systems were chosen that were relatively insensitive to cyclooxygenase inhibitors in order to reveal the unique activities of cytokine suppressive agents. The inhibitors exhibited significant activity in many such in vivo studies. Most notable are its effectiveness in the collagen-induced arthritis model and inhibition of TNF production in the endotoxic shock model. In the latter study, the reduction in plasma level of TNF correlated with survival and protection from endotoxic shock related mortality. Also of great importance are the compounds effectiveness in inhibiting bone resorption in a rat fetal long bone organ culture system. Griswold et al., (1988) Arthritis Rheum.
  • Another aspect of the present invention is to the novel use of these CSBP/cytokine inhibitors for the treatment of chronic inflammatory or proliferative or angiogenic diseases which are caused by excessive, or inappropriate angiogenesis.
  • Chronic diseases which have an inappropriate angiogenic component are various ocular neovasularizations, such as diabetic retinopathy and macular degeneration.
  • Other chronic diseases which have an excessive or increased proliferation of vasculature are tumor growth and metastasis, atherosclerosis, and certain arthritic conditions. Therefore CSBP kinase inhibitors will be of utility in the blocking of the angiogenic component of these disease states.
  • the term "excessive or increased proliferation of vasculature inappropriate angiogenesis" as used herein includes, but is not limited to, diseases which are characterized by hemangiomas and ocular diseases.
  • inappropriate angiogenesis includes, but is not limited to, diseases which are characterized by vesicle proliferation with accompanying tissue proliferation, such as occurs in cancer, metastasis, arthritis and atherosclerosis.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
  • This invention also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of formula (I) and a pharmaceutically acceptable carrier or diluent.
  • Compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation.
  • the compounds of formula (I) may be administered in conventional dosage forms prepared by combining a compound of formula (I) with standard pharmaceutical carriers according to conventional procedures.
  • the compounds of formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid.
  • solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
  • time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
  • a wide variety of pharmaceutical forms can be employed.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but preferably will be from about 25mg. to about lg.
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
  • Compounds of formula (I) may be administered topically, that is by non- systemic administration. This includes the application of a compound of formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation.
  • Lotions according to the present invention include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base.
  • the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel.
  • the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan esteror a polyoxyethylene derivative thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent.
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 _C. for half an hour.
  • the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
  • Compounds of formua (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • Compounds of formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration.
  • Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
  • the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg/kg, more preferably from about 0.5 mg to 15mg.
  • the daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg.
  • the daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily.
  • the daily inhalation dosage regimen will preferably be from about 0.01 mg kg to about 1 mg/kg per day.
  • the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • cytokine-inhibiting effects of compounds of the present invention were determined by the following in vitro assays: Interleukin - 1 (IL-1), Interleukin -8 (IL-8 ), and Tumour Necrosis Factor
  • TNF assays may be found in a number of publications, in particular suitable assays for use herein are described in Adams et al., US 5,593,992, whose disclosure is incorporated by reference.
  • mice and rats are injected with LPS.
  • mice Male Balb/c mice from Charles River Laboratories are pretreated (30 minutes) with compound or vehicle. After the 30 min. pretreat time, the mice are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma
  • mice 25 ug/mouse in 25 ul phosphate buffered saline (pH 7.0) intraperitoneally. Two hours later the mice are killed by CO2 inhalation and blood samples are collected by exsanguination into heparinized blood collection tubes and stored on ice. The blood samples are centrifuged and the plasma collected and stored at -20°C until assayed for TNF ⁇ by ELIS A. Rat Method
  • mice Male Lewis rats from Charles River Laboratories are pretreated at various times with compound or vehicle. After a determined pretreat time, the rats are given
  • LPS lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO
  • heparinized whole blood is collected from each rat by cardiac puncture 90 minutes after the LPS injection.
  • the blood samples are centrifuged and the plasma collected for analysis by ELISA for TNF ⁇ levels.
  • TNF ⁇ levels were measured using a sandwich ELISA, as described in Olivera et al., Circ. Shock, 37, 301-306, (1992), whose disclosure is incorporated by reference in its entirety herein, using a hamster monoclonal antimurine TNF ⁇ (Genzyme, Boston, MA) as the capture antibody and a polyclonal rabbit antimurine TNFa (Genzyme) as the second antibody.
  • a peroxidase-conjugated goat antirabbit antibody Pierce, Rockford, IL
  • TNF ⁇ levels in the plasma samples from each animal were calculated from a standard curve generated with recombinant murine TNF ⁇ (Genzyme).
  • Test compound concentrations were prepared at 10 X concentrations and
  • LPS prepared at 1 ug/ml (final cone, of 50 ng/ml LPS) and added in 50 uL volumes to 1.5 mL eppendorf tubes.
  • Heparinized human whole blood was obtained from healthy volunteers and was dispensed into eppendorf tubes containing compounds and LPS in 0.4 mL volumes and the tubes incubated at 37 C. Following a 4 hour incubation, the tubes were centrifuged at 5000 rpm for 5 minutes in a TOMY microfuge, plasma was withdrawn and frozen at -80 C.
  • Cytokine measurement IL-I and/or TNF were quantified using a standardized ELISA technology. An in-house ELISA kit was used to detect human IL-1 and TNF. Concentrations of IL-1 or TNF were determined from standard curves of the appropriate cytokine and IC50 values for test compound (concentration that inhibited 50% of LPS-stimulated cytokine production) were calculated by linear regression analysis.
  • CSBP Kinase Assay
  • This assay measures the CSBP-catalyzed transfer of 32p f r ⁇ m [a-32p]ATP to threonine residue in an epidermal growth factor receptor (EGFR)-derived peptide (T669) with the following sequence: KRELVEPL7PSGEAPNQALLR (residues 661-681).
  • EGFR epidermal growth factor receptor
  • KRELVEPL7PSGEAPNQALLR residues 661-681.
  • Kinase reactions (total volume 30 ul) contain: 25 mM Hepes buffer, pH 7.5; 10 mM MgCl2; 170 uM ATPO); 10 uM Na ortho vanadate; 0.4 mM T669 peptide; and 20-80 ng of yeast-expressed purified CSBP2 (see Lee et al., Nature 300, n(72),
  • 32P/MgATP Reactions are incubated at 30 °C for 10 min and stopped by adding 10 ul of 0.3 M phosphoric acid.
  • 32P-labeled peptide is separated on phosphocellulose (Wattman, p81) filters by spotting 30 ul reaction mixture. Filters are washed 3 times with 75 mM phosphoric acid followed by 2 washes with H2O, and counted for 32P.
  • the Km of CSBP for ATP was determined to be 170 uM. Therefore, compounds screened at the Km value of ATP.
  • Prostoglandin endoperoxide synthase-2 (PGHS-2) assay This assay describes a method for determining the inhibitory effects of compounds of Formula (I) on human PGHS-2 protein expression in LPS stimulated human monocytes.
  • a suitable assay for PGHS-2 protein expression may be found in a number of publications, including US Patent 5,593,992 whose disclosure is incorporated herein by reference.
  • This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats. Since TNF- a is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- a plays an important role in both the acute and regenerative response to CNS trauma.
  • a suitable assay may be found in WO 97/35856 whose disclosure is incorporated herein by reference.
  • This assay characterizes the regional expression of interleukin- l ⁇ (IL-l ⁇ ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-l ⁇ mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-l ⁇ play a role in the post- traumatic pathologic or regenerative sequelae of brain injury.
  • TBI lateral fluid-percussion traumatic brain injury

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel 2,4,5-triaryl substituted imidazole compounds and compositions for use in therapy of CSBP/RK/p38 mediated diseases.

Description

NOVEL ARYLOXY SUBSTITUTED PYRIMIDINE IMIDAZOLE COMPOUNDS
FIELD OF THE INVENTION
This invention relates to a novel group of aryloxypyrimidine substituted imidazole compounds, processes for the preparation thereof, the use thereof in treating cytokine mediated diseases and pharmaceutical compositions for use in such therapy.
BACKGROUND OF THE INVENTION
Intracellular signal transduction is the means by which cells respond to extracellular stimuli. Regardless of the nature of the cell surface receptor (e. g. protein tyrosine kinase or seven-transmembrane G-protein coupled), protein kinases and phosphatases along with phopholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C. Cell , 80, 179-278 (1995)]. Protein kinases can be categorized into five classes with the two major classes being, tyrosine kinases and serine / threonine kinases depending upon whether the enzyme phosphorylates its substrate(s) on specific tyrosine(s) or serine / threonine(s) residues [Hunter, T., Methods in Enzymologv (Protein Kinase Classification) p. 3, Hunter, T.; Sefton, B. M.; eds. vol. 200, Academic Press; San Diego, 1991].
For most biological responses, multiple intracellular kinases are involved and an individual kinase can be involved in more than one signaling event. These kinases are often cytosolic and can translocate to the nucleus or the ribosomes where they can affect transcriptional and translational events, respectively. The involvement of kinases in transcriptional control is presently much better understood than their effect on translation as illustrated by the studies on growth factor induced signal transduction involving MAP/ERK kinase [Marshall, C. J. Cell . 80, 179 (1995); Herskowitz, I. Cell . 80, 187 (1995); Hunter, T. Cell . 80, 225 (1995); Seger, R., and Krebs, E. G. FASEB J., 726-735 (1995)].
While many signaling pathways are part of cell homeostasis, numerous cytokines (e.g., IL-1 and TNF) and certain other mediators of inflammation (e.g., COX-2, and iNOS) are produced only as a response to stress signals such as bacterial lippopolysaccharide (LPS). The first indications suggesting that the signal transduction pathway leading to LPS-induced cytokine biosynthesis involved protein kinases came from studies of Weinstein [Weinstein, et al, J. Immunol. 151, 3829(1993)] but the specific protein kinases involved were not identified. Working from a similar perspective, Han [Han, et al., Science 265. 808(1994)] identified murine p38 as a kinase which is tyrosine phosphorylated in response to LPS. Definitive proof of the involvement of the p38 kinase in LPS-stimulated signal transduction pathway leading to the initiation of proinflammatory cytokine biosynthesis was provided by the independent discovery of p38 kinase by Lee [Lee, et al., Nature. 372, 739(1994)] as the molecular target for a novel class of anti-inflammatory agents. The discovery of p38 (termed by Lee as CSBP 1 and 2) provided a mechanism of action of a class of anti- inflammatory compounds for which SK&F 86002 was the prototypic example. These compounds inhibited IL-1 and TNF synthesis in human monocytes at concentrations in the low mM range [Lee, et al., Int. J. Immunopharmac. 10(7), 835(1988)] and exhibited activity in animal models which are refractory to cyclooxygenase inhibitors [Lee, et al.. Annals N. Y. Acad. Sci.. 696, 149(1993)].
MITOGEN AND STRESS ACTIVATED PROTEIN KINASE CASCADES
Figure imgf000004_0002
Figure imgf000004_0001
Figure 1
It is now firmly established that CSBP/p38 is a one of several kinases involved in a stress-response signal transduction pathway which is parallel to and largely independent of the analogous mitogen-activated protein kinase (MAP) kinase cascade (Figure 1). Stress signals, including LPS, pro-inflammatory cytokines, oxidants, UV light and osmotic stress, activate kinases upstream from CSBP/p38 which in turn phosphorylate CSBP/p38 at threonine 180 and tyrosine 182 resulting in CSBP/p38 activation. MAPKAP kinase-2 and MAPKAP kinase-3 have been identified as downstream substrates of CSBP/p38 which in turn phosphorylate heat shock protein Hsp 27 (Figure 2). It is not yet known whether MAPKAP-2, MAPKAP-3, Mnkl or Mnk2 are involved in cytokine biosynthesis or alternatively that inhibitors of CSBP/p38 kinase might regulate cytokine biosynthesis by blocking a yet unidentified substrate downstream from CSBP/p38 [Cohen, P. Trends Cell Biol.. 353-361(1997)].
p38 Kinase Pathway
LPS/IL-1/TNF stress/UV
I
Figure imgf000005_0001
Figure 2
What is known, however, is that in addition to inhibiting IL-1 and TNF, CSBP/p38 kinase inhibitors (SK&F 86002 and SB 203580) also decrease the synthesis of a wide variety of pro-inflammatory proteins including, IL-6, IL-8, GM-CSF and COX-2. Inhibitors of CSBP/p38 kinase have also been shown to suppress the TNF- induced expression of VCAM-1 on endothelial cells, the TNF-induced phosphorylation and activation of cytosolic PLA2 and the IL-1 -stimulated synthesis of collagenase and stromelysin. These and additional data demonstrate that CSBP/p38 is involved not only cytokine synthesis, but also in cytokine signaling [CSBP/P38 kinase reviewed in Cohen, P. Trends Cell Biol.. 353-361(1997)]. Interleukin- 1 (IL-1) and Tumor Necrosis Factor (TNF) are biological substances produced by a variety of cells, such as monocytes or macrophages. IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)]. The myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.
There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis, and acute synovitis. Recent evidence also links IL- 1 activity to diabetes and pancreatic β cells [review of the biological activities which have been attributed to IL-1 Dinarello, J. Clinical Immunology. 5 (5), 287-297 (1985)].
Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
Interleukin-8 (IL-8) is a chemotactic factor produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. Its production from endothelial cells is induced by IL- 1 , TNF, or lipopolysachharide (LPS). IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes, and basophils. In addition it induces histamine release from basophils from both normal and atopic individuals as well as lysozomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac- 1 (CDl lb/CD 18) on neutrophils without de novo protein synthesis, this may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many diseases are characterized by massive neutrophil infiltration. Conditions associated with an increased in IL-8 production (which is responsible for chemotaxis of neutrophil into the inflammatory site) would benefit by compounds which are suppressive of IL-8 production.
IL-1 and TNF affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
Inhibition of signal transduction via CSBP/p38, which in addition to IL-1, TNF and IL-8 described above is also required for the synthesis and/or action of several additional pro-inflammatory proteins (i.e., IL-6, GM-CSF, COX-2, collagenase and stromelysin), is expected to be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. This expectation is supported by the potent and diverse anti-inflammatory activities described for CSBP/p38 kinase inhibitors [Badger, et al, J. Pharm. Exp. Thera. 279 (3): 1453- 1461.(1996); Griswold, et al, Pharmacol. Comm. 7, 323-229 (1996)].
There remains a need for treatment in this field, for compounds which are cytokine suppressive anti-inflammatory drugs, i.e. compounds which are capable of inhibiting the CSBP/p38 RK kinase.
SUMMARY OF THE INVENTION
This invention relates to the novel compounds of Formula (I) and pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier.
This invention relates to a method of propylaxis, or the treatment of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective prophylatic or treatment amount of a compound of Formula (I). This invention also relates to a method of inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I). This invention more specifically relates to a method of inhibiting the production of IL- 1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
This invention more specifically relates to a method of inhibiting the production of IL-6 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
This invention more specifically relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
This invention more specifically relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
Accordingly, the present invention provides a compound of formula (I):
Figure imgf000008_0001
wherein: Ri is 4-pyrimidinyl ring which ring is substituted by Y, or NHRa, and is optionally substituted independently one to three times with Y, NHRa, optionally substituted C1-.4 alkyl, halogen, hydroxyl, optionally substituted Ci-4 alkoxy, optionally substituted C1-.4 alkylthio, optionally substituted C1-.4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(Rιo)C(O)Rb, N(Rιo)S(O)2Rd> or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or
NR15; Y is Xι-Ra; X\ is sulfur or oxygen; Ra is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylCi-6alkyl, wherein each of these moieties may be optionally substituted; Rb is hydrogen, Ci-6 alkyl, C3-.7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl; Rd is C ι_6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCι-4 alkyl; R2 is hydrogen, Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkylCi-ioalkyl, C5--7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, heterocyclyl, heterocyclylCi-io alkyl, (CRioR28)n OR12, (CRlθR28)n'ORl3, (CRlθR28)n' S(O)mR25, (CRlθR28)n S(O)2R25, (CRι oR28)n'NHS(O)2R25, (CRι0R28)n'NR8R9, (CRlθR28)n'NO2, (CRι0R28)n'CN, (CRι0R28)n'S(O)mNR8R9, (CRι0R28)n'C(Z)Rι3, (CRι0R28)n'C(Z)ORi3, (CRιoR28)n'C(Z)NR8R9. (CRi0R28)n'C(Z)NRi3ORi2,
(CRι0R28)n,NRlθC(Z)Ri3, (CRιoR28)n,NRlθC(Z)NR8R9, (CRι0R28)n'N(OR2l)C(Z)NR8R9, (CRlθR28)n'N(OR2l)C(Z)Ri3, (CRι0R28)n'C(=NOR2l)Rl3, (CRlθR28)n'NRioC(=NR27)NR8R9, (CRιoR28)n'OC(Z)NR8R9, (CRioR28)n'NRiθC(Z)ORιo) (CRιoR28)n'NRiθC(Z)ORιo, 5-(R25)-1.2,4-oxadizaol-3-yl or 4-(Ri2)-5-
(Rl8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl;wherein the cyclcoalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl moieties may be optionally substituted; n is 0 or an integer from 1 to 10; n' is an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; t is a number having a value of 1, 2 or 3; v is 0, or an integer having a value of 1 or 2;
Figure imgf000009_0001
Q is an aryl or heteroaryl group;
Z is oxygen or sulfur;
Yl is independently selected from hydrogen, C1-.5 alkyl, halo-substituted C1-.5 alkyl, halogen, or (CRιoR2θ)nY2;
Y2 is OR8, NO2, S(O)m,,Rl l, SRs, S(O)m"OR8, S(O)mNRsR9, NR8R9,
O(CRioR20)n'NR8R9. C(O)Rg, CO2R8, CO2(CRlθR2θ)n' CONR8R9, ZC(O)R8, CN, C(Z)NR8R9, NRιoC(Z)R8, C(Z)NR8OR9, NRioC(Z)NR8R9, NRlθS(O)m »Rn, N(OR2l)C(Z)NR8R9, N(OR2l)C(Z)R8, C(=NOR2l)R8, NRιoC(=NRi5)SRi 1,
Figure imgf000009_0002
1,
NRιoC(=CRi4R24)NR8R9, NRIQC(O)C(O)NR8R9, NR IQC(O)C(O)ORIO,
- 1 C(=NRi3)NR8R9, C(=NORi3)NR8R9, C(=NRi3)ZRn, OC(Z)NR8R9, NRιoS(O)m"CF3, NRioC(Z)ORιo, 5-(Rι8)-l,2,4-oxadizaol-3-yl or 4-(R 12)-5-(R 18R 19)-4,5-dihydro- 1 ,2,4-oxadiazol-3-yl; R4 is phenyl, naphth-1-yl or naphth-2-yl which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a
4-phenyl, 4-naphth-l-yl or 5-naphth-2-yl substituent, is halo,nitro, cyano, C(Z)NR7Ri7, C(Z)OR 3, (CRioR2θ)vCOR36, SR5, SOR5, OR36, halo- substituted-Ci-4 alkyl, C1-.4 alkyl, ZC(Z)R36, NRιoC(Z)R23, or (CRioR2θ)vNRioR20 and which, for other positions of substitution, is halo, nitro, cyano, C(Z)NRi6R26, C(Z)OR8, (CRιoR2θ)m"COR8, S(O)mR8, OR8, halo-substituted-Ci-4 alkyl, Ci_4 alkyl, CRιoR2θ)m"NRlθC(Z)R8, NRioS(O)m'Rn, NRioS(O)m'NR7Rl7, ZC(Z)R8 or (CRι0R2θ)m"NRl6R26; R5 is hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH; R7 and R17 is each independently selected from hydrogen or C1-.4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR22. R8 is hydrogen, heterocyclyl, heterocyclylalkyl or Ri 1; R9 is hydrogen, Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl or R8 and R9 may together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12; Rio and R20 is each independently selected from hydrogen or C1-.4 alkyl;
Rl 1 is Ci-io alkyl, halo- substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-.7 cycloalkyl, C5_7 cycloalkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; Rl2 is hydrogen, -C(Z)Ri3 or optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted arylCi-4 alkyl, or S(O)2R25» R13 is hydrogen, Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclylCi-io alkyl, aryl, arylCi-10 alkyl, heteroaryl or heteroaryl Ci-io alkyl, wherein all of these moieties may be optionally substituted; Rl4 and R24 is each independently selected from hydrogen, alkyl, nitro or cyano; Rl5 is hydrogen, cyano, Ci-4 alkyl, C3-.7 cycloalkyl or aryl; Ri6 and R26 is each independently selected from hydrogen or optionally substituted Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-Cι-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of
5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12 ; Rl8 and R19 is each independently selected from hydrogen, Cι_4 alkyl, substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl or together denote a oxygen or sulfur; R21 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, aryl Ci-4 alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, aroyl, or Ci-io alkanoyl ; R22 i Rl0 or C(Z)-Ci-4 alkyl;
R23 is C 1-4 alkyl, halo-substituted-Ci-4 alkyl, or C3-5 cycloalkyl;
R25 is C i-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, arylalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroarylalkyl; R27 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl, or aryl; R28 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety, all of which may be optionally substituted; R36 is hydrogen or R23; or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of cytokine inhibition or production. In particular, cytokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section, but in particular viral infections. Examples of such viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retro viral infections.
In compounds of Formula (I), Ri is a 4-pyrimidinyl ring, which ring is substituted by Y, or NHRa. The ring may also be optionally substituted independently one to three times with Y, NHRa, optionally substituted Ci-4 alkyl, halogen, hydroxyl, optionally substituted Ci-4 alkoxy, optionally substituted Ci-4 alkylthio, optionally substituted Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(Rιo)C(O)Rb, N(Rιo)S(O)2Rd, or an
N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15. Preferably, the ring is substituted by Y. Suitably, Y is Xι-Ra; and Xi is sulfur or oxygen, preferably oxygen.
Suitably, Ra is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylC 1 -6 alkyl, heteroaryl, or heteroarylCi-6alkyl, wherein each of these moieties may be optionally substituted. Preferably Ra is Cι_6alkyl, aryl, or arylCi-6alkyl. More preferably aryl, or arylCi-6alkyl. Suitably, Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCι_4alkyl, heterocyclyl, or heterocyclylC 1.4 alkyl; wherein each of these moieties may be optionally substituted.
Suitably, Rd is Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylC 1 -.4 alkyl; wherein each of these moieties may be optionally substituted.
A preferred ring placement on the 4-pyrimidinyl ring is at the 2-position, such as in 2-methoxy-pyrimidine or 2-phenxoy-pyrimidine.
Suitably, R2 is hydrogen, Ci-io alkyl, halo-substituted Cι_ιo alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-.7 cycloalkylCi-ioalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, heterocyclyl, heterocyclylC 1-10 alkyl, (CRιoR28)n OR12, (CRιoR28)n,ORi3, (CRioR28)n'
S(O)mR25, (CRl0R28)n S(O)2R25. (CRι0R28)n'NHS(O)2R25-
(CRι0R28)n'NR8R9, (CRlθR28)n'NO2, (CRioR28)n'CN,
(CRιoR28)n'S(O)mNR8R9, (CRι0R28)n'C(Z)Rι3, (CRι0R28)n'C(Z)ORι3, (CRιoR28)n'C(Z)NR8R9, (CRιoR28)n'C(Z)NRι3ORi2,
(CRι0R28)n'NRiθC(Z)Ri3, (CRιoR28)n'NRlθC(Z)NR8R9,
(CRιoR28)n'N(OR2l)C(Z)NR8R9, (CRιoR28)n'N(OR2l)C(Z)Ri3,
(CRιoR28)n'C(=NOR2l)Rl3, (CRlθR28)n'NRlθC(=NR27)NR8R9,
(CRιoR28)n'OC(Z)NR8R9, (CRιoR28)n'NRlθC(Z)ORιo, (CRιoR28)n'NRlθC(Z)ORιo, 5-(R25)-l,2,4-oxadizaol-3-yl or 4-(Ri2)-5-
(Rl8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl;wherein the cyclcoalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl moieties may be optionally substituted.
Preferably R2 is hydrogen, an optionally substituted heterocyclyl ring, and optionally substituted heterocyclylC ι_ 10 alkyl, an optionally substituted Cμio alkyl, an optionally substituted C3-7cycloalkyl, an optionally substituted C3_7cycloalkyl Cι_ι0 alkyl, (CRιoR28)n OR 12, (CRιoR28)n'C(Z)ORi3 group, (CRι0R28)n'NR8R9, (CRioR28)n'NHS(O)2R25, (CRlθR28)n'S(O)mR25. an optionally substituted aryl; an optionally substituted arylCi-io alkyl, (CRι0R28)n'ORl3, (CRiθR28)n'C(Z)Rι3, or
Figure imgf000013_0001
More preferably R2 is hydrogen, (CRιoR28)n OR12, an optionally substituted Ci-io alkyl, an optionally substituted heterocyclyl ring, an optionally substituted heterocyclylC l- 10 alkyl, an optionally substituted aryl, an optionally substituted Ci-io alkyl, an optionally substituted C3-7cycloalkyl, an optionally substituted C3-7cycloalkyl Ci-io alkyl, (CRιoR2θ)n'NR8R9, or (CRιoR2θ)n'C(Z)ORi3 group. Another prefered grouping for R2 is hydrogen, an optionally substituted heterocyclyl ring, an optionally substituted heterocyclylC ι_ 10 alkyl, an optionally substituted C3-7cycloalkyl, or an optionally substituted C3_7cycloalkyl Ci-io alkyl.
When R2 is an optionally substituted heterocyclyl the ring is preferably a morpholino, pyrrolidinyl, or a piperidinyl group. When the ring is optionally substituted the substituents may be directly attached to the free nitrogen, such as in the piperidinyl group or pyrrole ring, or on the ring itself. Preferably the ring is a piperidine or pyrrole, more preferably piperidine. heterocyclyl ring may be optionally substituted one to four times independently by halogen; Cj-4 alkyl; aryl, such as phenyl; aryl alkyl, such as benzyl - wherein the aryl or aryl alkyl moieties themselves may be optionally substituted (as in the definition section below); C(O)ORi3, such as the C(O)Cι_4 alkyl or C(O)OH moieties; C(O)H; C(O)Ci-4 alkyl, hydroxy substituted Ci-4 alkyl, Ci-4 alkoxy, S(O)mCi-4 alkyl (wherein m is 0, 1, or 2), NR10R2O (wherein Rio and R20 are independently hydrogen or Cι_4alkyl).
Preferably if the ring is a piperidine, the ring is attached to the imidazole at the 4-position, and the substituents are directly on the available nitrogen, i.e. a 1 -Formyl-4-piperidine, 1 -benzyl-4-piperidine, 1 -methyl-4-piperidine, l-ethoxycarbonyl-4-piperidine. If the ring is substituted by an alkyl group and the ring is attached in the 4-position, it is preferably substituted in the 2 or 6 position or both, such as 2,2,6,6-tetramethyl-4-piperidine. Similarly, if the ring is a pyrrole, the ring is attached to the imidazole at the 3-position, and the substituents are also directly on the available nitrogen.
When R2 is an optionally substituted heterocyclyl Ci-io alkyl group, the ring is preferably a morpholino, pyrrolidinyl, or a piperidinyl group. Preferably this alkyl moiety is from 1 to 4, more preferably 3 or 4, and most preferably 3, such as in a propyl group. Preferred heterocyclic alkyl groups include but are not limited to, morpholino ethyl, morpholino propyl, pyrrollidinyl propyl, and piperidinyl propyl moieties. The heterocyclic ring herein is also optionally substituted in a similar manner to that indicated above for the direct attachment of the heterocyclyl. When R2 is an optionally substituted C3-7cycloalkyl, or an optionally substituted C3-7cycloalkyl Ci-io alkyl, the cycloalkyl group is preferably a C5 to C6 ring.
The C3-7cycloalkyl, and C3-7cycloalkyl Ci-io alkyl ring may be optionally substituted one or more times independently by halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; Ci-io alkoxy, such as methoxy or ethoxy; S(O)m alkyl, wherein m is 0, 1, or 2, such as methyl thio, methylsulfinyl or methyl sulfonyl; amino, mono & di-substituted amino, such as in the NR7R17 group; or where the R7R17 may cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally includes an additional heteroatom selected from O/N/S; Ci-io alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; halosubstituted alkyl, such as CF3; hydroxy substituted Ci-ioalkyl; C(O)ORi3, such as the free acid or methyl ester derivative; an optionally substituted aryl, such as phenyl; an optionally substituted arylalkyl, such as benzyl or phenethyl; and further where these aryl or aryl alkyl moieties may also be substituted one to two times by halogen; hydroxy; Ci-io alkoxy; S(O)m alkyl; amino, mono & di- substituted amino, such as in the NR7R17 group; alkyl or halosubstituted alkyl.
When R2 is (CRιo 28)n' RsR9, R8 and R9 are as defined in Formula (I), preferably R8 and R9 are each independently selected from hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl or an optionally substituted aryl- Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12. It is recognized that in some instances this can yield the same moiety as a heterocyclic Ci-io alkyl moiety noted above which is also a suitable R2 variable. Preferably R8 and R9 are independently hydrogen, Ci-4 alkyl, preferably methyl, or benzyl. The n term is preferably 1 to 4, more preferably 3 or 4, and most preferably 3, such as in a propyl group. Preferred groups include, but are not limited to, aminopropyl, (N-methyl-N-benzyl)aminopropyl, (N- Phenyl-methyl)amino-l -propyl, or diethylamino propyl.
When R2 is a (CRιoR28)n'C(Z)ORi3 group, R13 is suitably hydrogen, C\. 4 alkyl, especially methyl. The n' term is preferably 1 to 4, more preferably 2 or 3, such as in an ethyl or propyl group. Preferred groups include, but are not limited to, carboxymethyl-1 -butyl, carboxy-1 -propyl, or 2-acetoxy ethyl.
When R2 is a (CRιoR28)n'S(O)mR25 group m is 0, 1, or 2, and Rι8 is preferably aryl, especially phenyl, or Ci-io alkyl, especially methyl. The n term is preferably 1 to 4, more preferably 2 or 3, such as in an ethyl or propyl group.
When R2 is a (CRιoR28)n'ORl3 group, Rπ is suitably hydrogen, aryl, especially phenyl, or Ci-io alkyl, especially methyl or ethyl. The n term is preferably 1 to 4, more preferably 2 or 3, such as in an ethyl or propyl group.
When R2 is a (CRιoR28)n'NHS(O)2R25 group, R25 is suitably alkyl, especially methyl. The n term is preferably 1 to 4, more preferably 2 or 3, such as in an ethyl or propyl group.
When R2 is a optionally substituted aryl, the aryl is preferably phenyl. The aryl ring may be optionally substituted one or more times, preferably by one or two substituents, independently selected from Ci-4 alkyl, halogen, especially fluoro or chloro, (CRioR28)tORl3, (wherein t is 0, or an integer of 1 to 4), (CRιo 28)t RioR20- especially amino or mono- or di-alkylamino (CRιoR28)tS(O)mR25, wherein m is 0, 1 or 2 ; SH, (CRioR2θ)nNR8R9, NRιoC(Z)R8 (such NHCO(Ci-io alkyl)), or NRιoS(O)mR25 (such as NHSO2(Ci-io alkyl)). Preferably the phenyl is substituted in the 3 or 4- position by (CRιoR28)tS(O)mR25, and R25 is preferably Ci-io alkyl, especially methyl.
When R2 is an optionally substituted heteroaryl or heteroarylalkyl group the ring may be optionally substituted one or more times, preferably by one or two substituents, independently selected from one or more times, by Ci-4 alkyl, halogen, especially fluoro or chloro, (CRιoR28)tORl3, (CRιoR28)tNRiθR20 . especially amino or mono- or di-alkylamino, (CRιoR28)tS(O)mR25> wherein m is 0, 1 or 2 ;
SH, (CRιoR28)n-NR8R9. NRιoC(Z)R8 (such NHCO(Cι_ιo alkyl));
NRιoS(O)mR25 (such as NHSθ2(Cι_ιo alkyl)); t is 0, or an integer of 1 to 4. One skilled in the art would readily recognize that when R2 is a
(CRioR28)nOC(Z)Ri3, or (CRιoR28)nOC(Z)NR8R9 moiety, or any similarly substituted group that n is preferably at least 2 which will allow for the synthesis of stable compounds.
Preferably R2 is hydrogen, Ci-4 alkyl (branched and unbranched), a methylthio propyl, a methylsulfinyl propyl, an amino propyl, N-methyl-N- benzylamino propyl group, diethylamino propyl, cyclopropyl methyl, morpholinyl butyl, morpholinyl propyl, a morpholinyl ethyl, a piperidine or a substituted piperidine. More preferably R2 is isopropyl; butyl; t-butyl; n-propyl; methylthiopropyl or methylsulfinyl propyl; morpholino propyl; morpholinyl butyl; phenyl substituted by halogen, thioalkyl or sulfinyl alkyl such as a methylthio, methylsulfinyl or methylsulfonyl moiety; piperidinyl; l-Formyl-4-piperidine; 1 -benzyl -4-piperidine; l-methyl-4-piperidine, or a l-ethoxycarbonyl-4-piperidine. Suitably, R3 is Q-(Yl)t, and Q is an optionally substituted aryl or heteroaryl moiety. Preferably, when Q is an aryl, it is phenyl, and when Q is a heteroaryl, preferred rings include thienyl, pyrrole, pyridine, or pyrimidine. More preferably, Q is a substituted phenyl. Preferably when t is 1 and R3 is mono-substituted phenyl, the substituent is located at the 4-position of the ring. Suitably, t is a number having a value of 1 to 3, preferably t is 1 or 2.
Suitably Yl is independently selected from hydrogen, C1-.5 alkyl, halo-substituted Ci-5 alkyl, halogen, or (CRιoR2θ)nY2.
Suitably, Y2 is OR8, NO2, S(O)m"Rl l, SR8, S(O)m"OR8, S(O)mNR8R9,
NR8R9, O(CRι0R20)n'NR8R9. C(O)R8, CO2R8, CO (CRιoR2θ)n' CONR8R9, ZC(O)R8, CN, C(Z)NR8R9, NRioC(Z)R8, C(Z)NR8OR9, NRιoC(Z)NR8R9, NRlθS(O)m-Rn, N(OR2l)C(Z)NR8R9, N(OR2l)C(Z)R8, C(=NOR2l)R8, NRιoC(=NRi5)SRn,
Figure imgf000016_0001
l, NRιoC(=CRi4R24)NR8R9, NRlθC(O)C(O)NR8R9, NRioC(O)C(O)ORio, C(=NRi3)NR8R9, C(=NORι3)NR8R9, C(=NRi3)ZRn, OC(Z)NR8R9. NRιoS(O)m"CF3, NRioC(Z)ORiθ, 5-(Ri8)-l,2,4-oxadizaol-3-yl or 4-(R 12)-5-(R 18R 19)-4,5-dihydro- 1 ,2,4-oxadiazol-3-yl.
Preferably when Q is substituted by 1 or 2 substituents, those substituents include halogen, Ci-5 alkyl and (CRιoR2θ)nY2 • The Y2 are preferably OR8, NO2, S(O)m'Rn, SR8, S(O)mNR8R9; NR8R9, O(CRι0R20)nNR8R9- C(O)R8, CO2 R8, CO2(CRioR20)n' CONR8R9, CN; C(Z)NR8R9, NRι0S(O)mRι 1 , NRιoC(Z)R8, NRι0C(Z)NR8R9, C(Z)NR8OR9, N(OR2l)C(Z)NR8R9, NRιoC(=NRi5)NR8R9, -C(=NORi3)NR8R9, 5-(Rι8)-l,2,4-oxadizaol-3-yl or 4- (R 12)-5-(R 18R 19)-4,5-dihydro- 1 ,2,4-oxadiazol-3-yl.
A preferred monosubstituent for Yi when the aryl or heteroaryl group Q is mono-substituted include (CRιoR2θ)nY2 wherein: n is preferably 0, 1, 2 or 3, more preferably 0 or 1; and Y2 is OR8, especially where R8 is hydrogen or Ci-io alkyl; NO2; S(O)m'Rι 1, especially where Ri 1 is Ci-io alkyl; SR8, especially where R8 is Ci-io alkyl; S(O)mNR8R9, especially where R8 and R9 is each hydrogen or Ci-io alkyl or R8 and R9 together with the nitrogen to which they are attached form a 5 to 7 membered ring which optionally includes another heteroatom selected from oxygen, sulfur or NR12 and m is 2; n' is 1 to 10; -NR8R9 , especially where R8 and R9 is each hydrogen, methyl or benzyl or R8 and R9 together with the nitrogen to which they are attached form a 5 to 7 membered ring which optionally includes another heteroatom selected from oxygen, sulfur or NR12; O(CRιoR2θ)nNR8R9, especially where R8 and R9 are each Ci-io alkyl; C(O)R , especially where R8 is hydrogen or Ci-io alkyl; CO2R8, especially where R8 is hydrogen or Ci-io alkyl; CO2(CRioR20)n' CONR8R9, especially where R8 and R9 is hydrogen or Ci-io alkyl; CN; C(Z)NR8R9, especially where R8 and R9 is hydrogen or Ci-io alkyl; NRιoS(O)mRι 1, especially where Rio is hydrogen or Ci-io alkyl and Rn is Ci-io alkyl or a halosubstituted; NRιoC(Z)R8, especially where R8 is Ci-io alkyl and Rio is hydrogen and Z is oxygen; C(Z)NR8OR9, especially where R8 and R9 is each hydrogen and Z is oxygen; NRιoC(Z)NR8R9, especially where R8 and R9 is each hydrogen or Ci-io alkyl and Z is oxygen; N(OR2l)C(Z)NR8R9, especially where R8 especially where R8, R9 and R21 is each hydrogen or Ci-io alkyl and Z is oxygen; -C(=NORi3)NR8R9, especially where R8, R9 and R13 is each hydrogen;
Figure imgf000017_0001
especially where R8 and R9 is hydrogen, Ci-io alkyl or arylalkyl and R15 is cyano; and 5-(Rι8)-l,2,4-oxadizaol-3-yl and 4-(Ri2)-5- (Rl8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl, especially where R12 is hydrogen and Rl8 and R19 is each hydrogen or Ci-io alkyl or together are oxo.
When Q is disubstituted prefered substituents include those hereinbefore noted for use when Q is mono-substituted and, as further substituent(s), halogen and Ci-io alkyl. When R3 is phenyl substituted with two or three substituents, the alkyl moieties preferably have from one to three carbons, more preferably one. Preferred phenyl ring positions for two substituents are the 3- and 4-positions and, for three substituents, the 3-, 4- and 5- positions. The substituent at the 3- and 5-positions is preferably Cι_2 alkyl, such as methyl, or halogen, such as bromo, fluoro or chloro, while the substituent at the 4-position is preferably hydroxyl.
More preferably Yl is (CRιoR20)nY2, and n is 0 or 1; Y2 is OH, or S(O)m'Ri 1, especially where Rn is Ci-io alkyl; SR8, especially where R8 is Cι_ 10 alkyl; NR8R9, especially where R8 and R9 is hydrogen, alkyl, aryl alkyl, or aryl or R8 and R9 together with the nitrogen to which they are attached form a pyrrolidinyl, piperidinyl or morpholinyl ring, more prefereably the R8 and R9 terms in the NR8R9 moiety are hydrogen, methyl or benzyl; CO2R8, especially where R8 is hydrogen or Ci-io alkyl; S(O)m'NR8R9, especially where R8 and R9 is each hydrogen or Cι_ιo alkyl; NRioS(O)mRl 1, especially where Rio is hydrogen and Ri 1 is Ci-io alkyl or 5-(Rl8)-l,2,4-oxadizaol-3-yl and 4-(Ri2)-5-(Rι8Ri9)-4,5- dihydro-l,2,4-oxadiazol-3-yl, especially where R12 is hydrogen and Rι8 and R19 is hydrogen or Cι_ιo alkyl or together are oxo.
Most preferably, Yl is methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, N,N-dimethylaminomethyl, N-benzyl-N-methylaminomethyl, N-morpholinomethyl, methanesulfonamido, sulphonamidomethyl, 5-methyl-4,5- dihydro-l,2,4-oxadiazol-3-yl or 5,5-dimethyl-4,5-dihydro-l,2,4-oxadiazol-3-yl.
In all instances herein where there is an alkenyl or alkynyl moiety as a substituent group, such as in R5, R8, R9, or Ri 1 the unsaturated linkage, i.e., the vinylene or acetylene linkage is preferably not directly attached to the nitrogen, oxygen or sulfur moieties, for instance in Y2 as C(Z)NR8OR9, NRιoC(Z)NR8R9, or OR8.
As used herein, "optionally substituted" unless specifically defined shall mean such groups as halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted Ci-ioalkyl; Ci-io alkoxy, such as methoxy or ethoxy; halosubstituted Ci-io alkoxy; S(O)m alkyl, wherein m is 0, 1 or 2, such as methyl thio, methylsulfinyl or methyl sulfonyl; amino, mono & di-substituted amino, such as in the NR7R17 group; or where the R7R17 may together with the nitrogen to which they are attached cyclize to form a 5 to 7 membered ring which optionally includes an additional heteroatom selected from O/N/S; Cι_ιo alkyl, cycloalkyl, or cycloalkyl alkyl group, such as methyl, ethyl, propyl, isopropyl, t-butyl, etc. or cyclopropyl methyl; halosubstituted Ci-io alkyl, such CF3; an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, wherein these aryl moieties may also be substituted one to two times by halogen, hydroxy, hydroxy substituted alkyl, Ci-io alkoxy, S(O)m alkyl, amino, mono & di-substituted amino, such as in the NR7R17 group, Ci-io alkyl, or CF3.
Preferred substitutions for R4 when it is a 4-phenyl, 4-naphth-l-yl or 5- naphth-2-yl moiety are one or two substituents each independently selected from halogen, SR5, SOR5, OR36, or (CRio 2θ)mNRlθR20- and for other positions of substitution on these rings preferred substitution is halogen, S(O)mR8, OR8, (CRioR20)mNRl6R26, NRιoC(Z)R8 and NRιoS(O)mRι 1. More preferred substituents for the 4-position in phenyl and naphth-1-yl and on the 5 -position in naphth-2-yl include halogen, especially fluoro and chloro, and SR5 and SOR5 wherein R5 is preferably a Ci-2 alkyl, more preferably methyl; of which fluoro is especially preferred. Preferred substituents for the 3-position in phenyl and naphth- 1-yl include: halogen, especially chloro; OR8, especially Ci-4 alkoxy; amino; NRIQC(Z)R8, especially NHCO(Cι_ιo alkyl); and NRιoS(O)mRl l, especially NHSθ2(Cι_ιo alkyl). Preferably, the R4 moiety is an unsubstituted or substituted phenyl moiety. More preferably, R4 is phenyl or phenyl substituted at the 4-position with fluoro and/or substituted at the 3-position with fluoro, chloro, Ci-4 alkoxy, methanesulfonamido or acetamido. A preferred grouping of Formula (I) are those compounds wherein Rj is a 4- pyrimidiny ring, which ring is substituted by Y, and R2 is hydrogen, an optionally substituted Cι_ιo alkyl, optionally substituted C3-7cycloalkyl, or an optionally substituted C3-7cycloalkyl C -io alkyl, an optionally substituted aryl, an optionally substituted heterocyclic alkyl, an optionally substituted heterocyclic, optionally substituted heteroaryl or heteroarylalkyl, (CRιoR28)n'ORl3?
(CRioR28)n'S(O)mR25, (CRi0R28)n'NR8R9, (CRi0R28)n'C(Z)ORi3, (CRιoR28)n'NHS(O)2R25. (CRi0R28)n'C(Z)Rι3, or
(CRιoR28)n'C(=NOR2l)Rl3; and Ri, R3, and R4 are as defined for Formula (I). More preferred are those compounds wherein R2 is a Ci-4 alkyl (branched and unbranched), such as isopropyl, butyl, t-butyl, n-propyl, a methylthio propyl, a methylsulfinyl propyl, an amino propyl, N-methyl-N-benzylamino propyl group, (phenylmethyl)amino- 1 -propyl, diethylamino propyl, cyclopropyl methyl, morpholinyl butyl, morpholinyl propyl, morpholinyl ethyl, l-Formyl-4-piperidinyl, 1 -benzyl-4-piperidinyl, 1 -methyl-4-piperidinyl, 1 -ethoxycarbonyl-4-piperidinyl, phenyl substituted by halogen, thioalkyl or sulfinyl alkyl such as a methylthio, methylsulfinyl or methylsulfonyl moiety; and Ri, R3, and R4 are as defined for
Formula (I).
Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent Yi in R3 comprises a carboxy group. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quarternary ammonium cations.
The following terms, as used herein, refer to:
• "halo" - all halogens, that is chloro, fluoro, bromo and iodo; • "Cι_ oalkyl" or "alkyl" - both straight and branched chain radicals of 1 to
10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, n-propyl, i-yø-propyl, n-butyl, -sec-butyl, sø-butyl, tert- butyl, and the like;
• "cycloalkyl" is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
• "cycloalkenyl" is used herein to mean cyclic radicals, preferably of 5 to 8 carbons, which have at least one bond including but not limited to cyclopentenyl, cyclohexenyl, and the like.
• "aryl" - phenyl and naphthyl; • "heteroaryl" (on its own or in any combination, such as "heteroaryloxy") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole; • "heterocyclic" (on its own or in any combination, such as
"heterocyclylalkyl") - a saturated or wholly or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, imidazolidine or pyrazolidine; • "aroyl" - a C(O)Ar, wherein Ar is as phenyl, naphthyl, or aryl alkyl derivative such as defined above, such group include but are note limited to benzyl and phenethyl;
• "alkanoyl" - a C(O)Ci-ioalkyl wherein the alkyl is as defined above;
• "sulfinyl" - the oxide S(O) of the corresponding sulfide, while the term "thio" refers to the sulfide;
• "aralkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean an aryl, heteroaryl or heterocyclic moiety as respectively defined above said group connected to Cι_6 alkyl group as also defined above unless otherwise indicated.
It is recognized that the compounds of the present invention may exist as stereoisomers, regioisomers, or diastereiomers. These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are included within the scope of the present invention. For the purposes herein of nomenclature, the compounds of formula (I) are named by their position corresponding to:
Figure imgf000021_0001
Exemplified compounds of formula (I) include: 2-(4-Methylthiophenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)imidazole; 2-(4-Methylsulfinylphenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidiny l)imidazole ; 2-[(4-N,N-Dimethyl)aminomethylphenyl]-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole; 2-[(4-N,N-Dimethyl)aminomethylphenyl]-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyridminyl)imidazole;
(+/-) 2-(4-Methylsulfinylphenyl]-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyridminyl)imidazole ; 2-(4-Methylthiophenyl]-4-(4-fluorophenyl)-5-(2-phenoxy-4-pyridminyl)imidazole; and pharmaceutically acceptable salts thereof. Compounds of formula (I) are imidazole derivatives which may be readily prepared using procedures well-known to those skilled in the art, and described in, for instance, Comprehensive Heterocyclic Chemistry, ed Katritzky and Rees, Pergamon Press, 1984, 5, 457-497, from starting materials which are either commercially available or can be prepared from such by analogy with well-known processes. A key step in many such syntheses is the formation of the central imidazole nucleus, to give compounds of formula (I). Suitable procedures are described in inter alia US patent nos. 3,707,475 and 3,940,486 which are herein incorporated by reference in their entirety. These patents describe the synthesis of a- diketones and a-hydroxyketones (benzoins) and their subsequent use in preparing imidazoles and N-hydroxyl imidazoles. Thereafter, further compounds of formula (I) may be obtained by manipulating substituents in any of the groups Ri, R2, R3 and R4 using conventional functional group interconversion procedures.
Alternative synthesis for making compounds of Formula (I) are described in USSN 08/481,671, Adams et al.; and in PCT/US93/00674, now US patent 5,686455, Adams et al., whose disclosures are incorporated by reference herein in their entirety. Scheme I
Figure imgf000022_0001
A benzoic acid is treated with N-methoxymethylamine, EDC and 1-hydroxy- benzotriazole to give N-methoxy,N-methyl-4-fluorobenzamide 4. Deprotonation of 4-methyl-2-thiomethylpyrimidine with a strong base such as lithium diisopropylamide followed by treatment with 4 yields an intermediate ketone, which upon treatment with an oxidant such as m-CPBA in an organic solvent such as methylene chloride followed by addition of an alkoxide or phenoxide yields alkoxy - or phenoxy-pyrimidine 5. This ketone may be treated with sodium nitrite and aqueous HCl to give keto-oxime 6. The keto-oxime is condensed with a substituted aromatic aldehyde and ammonium acetate in acetic acid to give imidazole-N-oxide 7. Treatment of the N-oxide with triethyl phosphite in an organic solvent such as
N,N-dimethylacetamide or dimethylformamide at 100 C yields 8. In cases where R2 contains a thioether, treatment with an oxidant such as Oxone in an organic solvent such as methylene chloride yields the sulfoxide and sulfone 9.
A primary amine R3NH2 is treated (in Scheme II below) with 4- bromomethyl-2-methylthio-pyrimidine, 10 (prepared according to the procedure by Lucjan, S. et al, J. Org. Chem. 56, 5610, 1991), to give 11 which is then converted to the amide 12 by standard techniques. Deprotonation of 12 with a strong amide base, such as lithium di-/sø-propyl amide or sodium /^-(trimethylsily amide, followed by addition of an aryl nitrile to give the imidazole 13. Oxidation and displacement of the methylthio group as described above for compound 4 affords the alkoxypyrimidine 14.
Scheme II
Figure imgf000023_0001
Once the imidazole nucleus has been established, further compounds of formula (I) which may be prepared by applying standard techniques for functional group interconversion, for instance: C(O)NR8R9 from CO2CH3 by heating with or without catalytic metal cyanide, e.g. NaCN, and HNR8R9 in CH3OH; OC(O)R8 from OH with e.g.,ClC(O)R8 in pyridine; NRιo-C(S)NR8R9 from NHR10 with an alkylisothiocyante or thiocyanic acid; NR6C(O)OR6 from NHR6 with the alkyl chloroformate; NRIQC(O)NR8R9 from NHR10 by treatment with an isocyanate, e.g. HN=C=O or R10N=C=O; NRιo-C(O)R8 from NHRio by treatment with Cl-C(O)R8 in pyridine;
Figure imgf000024_0001
from C(NR8R9)SR8 with H3NR8+OAc" by heating in alcohol;
C(NR R9)SR8 from C(S)NR8R9 with R6-I in an inert solvent, e.g. acetone;
C(S)NR8R9 (where R8 or R9 is not hydrogen) from C(S)NH2 with HNR8R9, C(=NCN)-NR8R9 from C(=NR8R9)-SR8 with NH2CN by heating in anhydrous alcohol, alternatively from C(=NH)-NR8R9 by treatment with BrCN and NaOEt in
EtOH;
Figure imgf000024_0002
NRioSO2 8 from NHR10 by treatment with ClSO2R8 by heating in pyridine;
NRιoC(S)R8 from NRιoC(O)R8 by treatment with Lawesson's reagent [2,4-bis(4- methoxyphenyl)-l,3,2,4-dithiadiphosphetane-2,4-disulfide]; NR10SO2CF3 from NHR6 with triflic anhydride and base; NRιoC(O)-C(O)-OR8 from NHR10 with, e.g. methyloxalyl chloride and a base such as triethylamine; NRιoC(O)-C(O)-NR R9 from
NRιoC(O)-C(O)-OR8 with HNR8R9; and l-(NRιo)-2-imidazolyl from C(=NH)NHRιo by heating with 2-chloroacetaldehyde in chloroform (wherein R8, R9 and Rio are as hereinbefore defined.
Suitably, R6 is Ci-4 alkyl, halo-substituted-Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or C3-5 cycloalkyl.
Compounds of Formula (I) in which R2 is hydrogen may be readily converted into further compounds of formula (I) in which R2 is other than hydrogen, for instance alkyl, by conventional procedures such as alkylation or acylation followed by reduction. Such methods are in general relatively inefficient as they lack regiospecificty and the desired N-l product has to be separated from the mixture of N-l and N-3 products, for instance by chromatography or fractional crystallisation. Suitable protecting groups for use with hydroxyl groups and the imidazole nitrogen are well known in the art and described in many references, for instance, Protecting Groups in Organic Synthesis, Greene T W, Wiley-Interscience, New York, 1981. Suitable examples of hydroxyl protecting groups include silyl ethers, such as t-butyldimethyl or t-butyldiphenyl, and alkyl ethers, such as methyl connected by an alkyl chain of variable link, (CRιoR2θ)n- Suitable examples of imidazole nitrogen protecting groups include tetrahydropyranyl.
It should be noted that the compounds of Formula (I), where R4 may be an alkylsulfinyl, arylsulfinyl, alkylsulfonyl, or arylsulfonyl are prodrugs which are reductively converted in vivo to the corresponding alkylthio or arylthio form. Pharmaceutically acid addition salts of compounds of formula (I) may be obtained in known manner, for example by treatment thereof with an appropriate amount of acid in the presence of a suitable solvent.
The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.
Synthetic Examples
Example 1 2-(4-Methylthiophenyl)-4-(4-fluorophenyl -5-(2-methoxy-4-pyrimidinyl)imidazole a) N-Methyl.N-methoxy-4-fluorobenzamide
To a mixture of 4-fluorobenzoic acid (5.0 grams (hereinafter "g"), 36 millimoles (hereinafter "mmol")) and N,O-dimethylhydroxylamine hydrochloride (3.8 g, 39 mmol) in 200 mL of CH2Cl2 at 0 °C was added triethylamine (5.0 milliliters (hereinafter "mL"), 36 mmol). The solution was warmed to room temperature and 4-dimethylaminopyridine (0.2 g, 1.6 mmol) and l-(dimethylaminopropyl)-3-ethylcarbodiimide (6.8 g, 36 mmol) were added. The resulting solution was stirred for 16 hours (hereinafter "h"). Next, the solution was diluted with 200 mL of ethyl acetate and washed with 100 mL of saturated NaHCO3, 50 mL of H2O, twice with 50 mL of IN HCl, and 50 mL of H2O. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to give a light yellow oil. The oil was purified by chromatography through a plug of silica gel with 50% ethyl acetate/hexane to give title compound as a light yellow oil (5.5 g, 85%). ES (+) MS m/e = 184 (MH+) b) 4-(2-Methylthiopyrimidinyl)methyl-4-fluorophenylketone
To a solution of lithium diisopropylamide (29.5 mmol) in 40 mL ethylene glycol dimethyl ether at -20 C was added a cooled solution of 2-methylthio-4- methylpyrimidine (3.17 g, 22.7 mmol) in 10 mL of ethylene glycol dimethyl ether via cannula. The resulting solution was stirred for 30 min and then treated with a cooled solution of N-methyl,N-methoxy-4-fluorobenzamide (4.56 g, 24.9 mmol) in
10 mL of ethylene glycol dimethyl ether via cannula. This solution was warmed to room temperature and then heated at 40 C for 1 h. Next, the solution was cooled to room temperature and 300 mL of H2O were added. The mixture was extracted thrice with 150 mL of ethyl acetate. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to give an orange solid.
The solid was purified by chromatography through a plug of silica gel with 20-40% ethyl acetate/hexane to give 5 g of a dark yellow solid. This solid was recrystallized from ethyl ether/hexane to give the title compound as yellow needles (4.2 g, 70%). ES (+) MS m/e = 263 (MH+) c) 4-(2-Methoxypyrimidinyl)methyl-4-fluorophenylketone To a solution of 4-(2-methylthiopyrimidinyl)methyl-4-fluorophenylketone
(1.5 g, 5.7 mmol) in 75 mL of CH2C12 at 0 °C was added 85% 4- chloroperoxybenzoic acid (1.39 g, 6.8 mmol) and the resulting solution was stirred for 2 h. The solution was washed with 30 mL of 20% Na2S2θ5 , 30 mL of sat.
NaHCO3, and 30 mL brine. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to give 4-(2-methylsulfinylpyrimidinyl)methyl-
4-fluorophenylketone as a yellow solid.
To a solution of 4-(2-methylsulfinylpyrimidinyl)methyl-4- fluorophenylketone (5.7 mmol) in 75 mL THF was added 22 mL of 25% NaOMe in
MeOH at 0 C. The solution was warmed to room temperature and stirred for lh. The solution was then heated at 50 C for 30 min. Next, the solution was cooled,
200 mL of H2O were added and it was extracted thrice with 100 mL of ethyl acetate.
The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to give a solid. The solid was then purified by silica gel chromatography with 15-30% ethyl acetate/hexane to give the title compound as a light yellow solid (0.8 g, 57%). ES (+) MS m/e = 247 (MH+) d) 1 -(2-Methoxy-4-pyrimidyl)-2-(4-fluorophenyl)-ethanedione- 1 -oxime
To a suspension of 4-(2-methoxypyrimidinyl)methyl-4-fluorophenylketone
(0.70 g, 2.9 mmol) in 32 mL of 1: 1 3N HCl:dioxane was added a solution of sodium nitrite (0.24 g, 3.4 mmol) in 8 mL of H2O. The mixture was stirred for 3.5 h and then made basic by addition of NH4OH (cone). The mixture was extracted thrice with 50 mL ethyl ether. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound as a light green solid (0.87 g, quantitative). ES (+) MS m/e = 276 (MH+) e) 2-(4-Methylthiophenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyDimidazole-N-oxide
To 1 -(2-methoxy-4-pyrimidinyl)-2-(4-fluorophenyl)-ethanedione, 1 -oxime
(0.44 g, 1.4 mmol) in 16 mL of acetic acid was added 4-methylthiobenzaldehyde (0.29 mL, 2.1 mmol) and NH4OAC (0.88 g, 11.4 mmol). The resulting solution was heated to reflux for 24 h, cooled and poured into 100 mL of H2O. The solution was made basic with by addition of NH4OH (cone.) and extracted thrice with 50 mL of
CH2CI2. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to give an orange oil. The oil was purified by silica gel chromatography with 30-60% ethyl acetate/hexane to give the title compound as a yellow-orange solid (0.18 g, 28%). ES (+) MS m/e = 409 (MH+) f) 2-(4-Methylthiophenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinvDimidazole
To a solution of 2-(4-methylthiophenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole (0.16 g, 0.38) in 4 mL of N,N-dimethylacetamide was added triethyl phosphite (0.10 mL, 0.57 mmol) and the solution was heated overnight at
100 C. More triethyl phosphite (0.066 mL, 0.38 mmol) was added and the solution was heated at 100 C for an additional 4 h. The solution was concentrated to a small volume under reduced pressure and H2O was added. The mixture was extracted thrice with 20 mL CH2CI2. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to give a yellow oil. The oil was purified by silica gel chromatography with 20-50% ethyl acetate/hexane to give an orange oil which precipitated upon addition of a small amount of acetonitrile. The precipitate was triturated with hexane to remove residual amount of triethyl phosphite to give a yellow solid (0.11 g, 99%). ES (+) MS m/e = 393 (MH+)
Example 2 2-(4-Methylsulfinylphenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyDimidazole
To a solution of 2-(4-methylthiophenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole (0.10 g, 0.25 mmol) in 10 mL of THF at 0 C was added a cooled solution of Oxone (0.084 g, 0.28 mmol)in 10 mL of H2O. The solution was warmed to room temperature and stirred for 20 min. Next, 20 mL of NaHCO3 sat was added and the mixture was extracted thrice with 20 mL of CH2CI2. The combined organic layers were washed with 20 mL of 20% NaS2θ5 and brine and then dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was then purified by silica gel chromatography with 2-6% CH3OH/ CH2CI2 to give the title compound as a light yellow solid (0.084 g, 82%). ES (+)
MS m/e = 409 (MH+) Example 3
2-[(4-N,N-Dimethyl)aminomethyIphenyl]-4-(4-fluorophenyI)-5-(2-methoxy-4- pyrimidinyDimidazole a) 4-N.N-Dimethylaminomethylbenzaldehyde diethylacetal To a solution of dimethylamine hydrochloride (16.6 g 204 mmol) in 120 mL of methanol was added potassium hydroxide (3.6 g, 64 mmol). The mixture was stirred for 10 min at room temperature and 4-(diethoxymethyl)benzaldehyde (29.4 g4 141 mmol) was added. The mixture was cooled to 0 C, and sodium cyanoborohydride was added. The reaction was stirred at it for 2.5 h. The mixture was made basic with 10% sodium hydroxide at 0 C. The mixture was filtered, and the filtrate was evaporated under reduced pressure. The residue was acidified with 3 N hydrochloric acid at 0 C and washed with ether. The aqueous layer was made basic with 10% sodium hydroxide, extracted with methylene chloride (2X), the combined organic extracts were dried (MgSO4), evaporated under reduced pressure and the residue purified by silica gel chromatography to yield 19 g of the title compound. *H NMR (CDCI3) d 1.22 (t, J = 6.3 Hz, 6H), 2.23 (s, 6H), 3.40 (s, 2H),
3.5-3.7 (m, 4H), 5.49 (s, 1H), 7.29 (d, J = 9 Hz , 2H), 7.41 (d, J = 9 Hz, 2H). b) 2-r(4-N.N-Dimethyl)aminomethylphenyl]-4-(4-fluorophenyl)-5-(2-methoxy- 4-pyrimidinyl)imidazole-N-oxide To l-(2-methoxy-4-pyrimidinyl)-2-(4-fluorophenyl)-ethanedione, 1 -oxime
(0.43 g, 1.4 mmol) in 16 mL of acetic acid was added 4-N,N- dimethylaminomethylbenzaldehyde diethylacetal (0.50 g, 2.1 mmol) and NH4OAC
(0.88 g, 11.4 mmol). The resulting solution was heated 120 C for 20 hours, cooled and poured into 150 mL of H2O. The solution was made basic with by addition of NH4OH (cone.) and extracted thrice with 50 mL of CH2CI2. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure.
The residue was then purified by chromatography through a plug of silica gel with 10-30% CH3OH/CH2CI2 to give the title compound as a yellow foam (0.30 g,
50%). ES (+) MS m/e = 420 (MH+) c) 2-r4-(N.N-Dimethylaminomethyl)phenyl1-4-(4-fluorophenyl)-5-(2-methoxy-
4-pyrimidinyl)imidazole
To a solution of 2-[4-(N,N-Dimethylaminomethyl)phenyl]-4-(4- fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)imidazole-N-oxide (0.24 g, 0.58) in 7 mL of N,N-dimethylacetamide was added triethyl phosphite (0.30 mL, 1.74 mmol) and the solution was heated at 110 C overnight. The solution was concentrated to a small volume under reduced pressure and H2O was added. The mixture was extracted thrice with 20 m-L of CH2CI2. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to give a yellow oil. The oil was dissolved in 20 mL of H2O with 3 mL of 3 N HCl and washed thrice with 10 mL of ethyl acetate. The aqueous solution was made basic with 1 mL of 50 % NaOH and extracted thrice with 20 mL of CH2CI2. The oil was triturated with hexane to remove any residual amount of P(OEt)3. The oil was purified by reverse phase preparative HPLC to give the TFA salt of the title compound as a yellow solid (0.034 g, 7.6 %). ES (+) MS m/e = 404 (MH+)
Example 4
2-(4-Methylthiophenyl -4-(4-fluorophenyl)-5-(2-phenoxy-4-pyrimidinyl)imidazole a) 4-(2-Phenoxypyrimidinyl)methyl-4-fluorophenylketone
To a solution of 4-(2-methylthiopyrimidinyl)methyl-4-fluorophenylketone (1.5 g, 5.7 mmol) in 75 mL of CH C12 at 0 °C was added 85% 4- chloroperoxybenzoic acid (1.39 g, 6.8 mmol) and the resulting solution was stirred for 1 h at room temperature. The solution was washed with 30 mL of 20% Na2S2θ5 , 30 mL of sat. NaHCO3, and 30 mL of brine. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to give 4-(2- methylsulfinylpyrimidinyl)methyl-4-fluorophenylketone as a yellow solid. To a solution of phenol (2.72 g, 29 mmol) in 100 mL of dry THF at 0 °C was added 60% sodium hydride in mineral oil (0.55 g, 13.8 mmol) and the mixture was warmed to room temperature. To the suspension of sodium phenoxide was added a solution of 4-(2-methylsulfinylpyrimidinyl)methyl-4-fluorophenylketone (5.7 mmol) in 10 mL of THF. The mixture was heated at 50 C for 16 h. The mixture was concentrated under reduced pressure and 10 mL of N,N-dimethylacetamide was added. The resulting solution was heated at 80 C for lh. The solution was cooled, 200 mL of H2O were added and the resulting mixture was extracted thrice with 100 mL of ethyl acetate. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to give a solid. The solid was then purified by silica gel chromatography with 20-40% ethyl acetate/hexane to give the title compound as a light yellow solid (0.79 g, 44%). ES (+) MS m/e = 309 (MH+) b) 1 -(2-Phenoxy-4-pyrimidinylV2-(4-fluorophenyl)-ethanedione, 1 -oxime
Following the procedure of Example Id except using 4-(2-phenoxy- pyrimidinyl)methyl-4-fluorophenylketone afforded the title compound as a yellow foam in 91 % yield. ES (+) MS m/e = 338 (MH+) c) 2-(4-Methylthiophenyl)-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyrimidinyl)imidazole-N-oxide
Following the procedure of Example le except using l-(2-phenoxy-4- pyrimidinyl)-2-(4-fluorophenyl)-ethanedione, 1 -oxime afforded the title compound as a yellow solid in 85% yield. ES (+) MS m/e = 471 (MH+) d) 2-(4-Methylthiophenyl)-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyrimidinyDimidazole
Following the procedure of Example If except using 2-(4-methylthiophenyl)- 4-(4-fluorophenyl)-5-(2-phenoxy-4-pyrimidinyl)imidazole-N-oxide afforded the title compound as a yellow foam in 75% yield. ES (+) MS m/e = 455 (MH+)
Example 5
2-(4-Methylsulfinylphenyl)-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyrimidinyDimidazole Following the procedure of Example 2 except using 2-(4-methylthiophenyl)-
4-(4-fluorophenyl)-5-(2-phenoxy-4-pyrimidinyl)imidazole afforded the title compound as a white solid (after crystallizing from a small amount of CH2CI2) in
60% yield. ES (+) MS m/e = 471 (MH+)
Example 6
2-[4-(N.N-Dimethylaminomethyl)phenyl1-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyrimidinyDimidazole a) 2-[4-(N.N-Dimethylaminomethyl)phenyl]-4-(4-fluorophenyl)-5-(2-phenoxy- 4-pyrimidinyl imidazole-N-oxide Following the procedure of Example 3b except using l-(2-phenoxy-4- pyrimidinyl)-2-(4-fluorophenyl)-ethanedione, 1 -oxime afforded the title compound as a yellow foam in 57% yield. ES (+) MS m/e = 482 (MH+) b) 2-r4-(N.N-Dimethylaminomethyl)phenyll-4-(4-fluorophenyl)-5-(2-phenoxy- 4-pyrimidinyl imidazole To a solution of 2-[4-(N,N-Dimethylaminomethyl)phenyl]-4-(4- fluorophenyl)-5-(2-phenoxy-4-pyrimidinyl)imidazole-N-oxide (0.32 g, 0.66 mmol) in
5 mL of N,N-dimethylacetamide was added triethyl phosphite (0.34 mL, 2.0 mmol) and the solution was heated at 95 C overnight. The solution was concentrated to a small volume under reduced pressure and H2O was added. The mixture was extracted thrice with 20 mL of CH2CI2. The combined organic layers were dried over MgSU4, filtered and concentrated under reduced pressure to give a yellow oil. The oil was purified by silica gel chromatography using 5-15% CH3OH/CH2CI2 to give the title compound as a yellow foam (0.094 g, 30%). ES (+) MS m/e = 466 (MH+)
METHODS OF TREATMENT
The compounds of Formula (I) or a pharmaceutically acceptable salt thereof can be used in the manufacutre of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated cytokine producution by such mammal's cell, such as but not limited to monocytes and/or macrophages.
Compounds of formula (I) are capable of inhibiting proinflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF and are therefore of use in therapy. IL- 1, IL-6, IL-8 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte-derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these pro-inflammatory cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
Compounds of Formula (I) are capable of inhibiting inducible proinflammatory proteins, such as COX-2, also referred to by many other names such as prostaglandin endoperoxide synthase-2 (PGHS-2) and are therefore of use in therapy. These proinflammatory lipid mediators of the cyclooxygenase (CO) pathway are produced by the inducible COX-2 enzyme. Regulation, therefore of COX-2 which is responsible for the these products derived from arachidonic acid, such as prostaglandins affect a wide variety of cells and tissues are important and critical inflammatory mediators of a wide variety of disease states and conditions. Expression of COX-1 is not effected by compounds of Formula (I). This selective inhibition of COX-2 may alleviate or spare ulcerogenic liability associated with inhibition of COX- 1 thereby inhibiting prostoglandins essential for cytoprotective effects. Thus inhibition of these proinflammatory mediators is of benefit in controlling, reducing and alleviating many of these disease states. Most notably these inflammatory mediators, in particular prostaglandins, have been implicated in pain, such as in the sensitization of pain receptors, or edema. This aspect of pain management therefore includes treatment of neuromuscular pain, headache, cancer pain, and arthritis pain. Compounds of Formula (I) or a pharmaceutically acceptable salt thereof, are of use in the prophylaxis or therapy in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme. Accordingly, the present invention provides a method of inhibiting the synthesis of COX-2 which comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides for a method of prophylaxis treatment in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme.
Accordingly, the present invention provides a method of treating a cytokine- mediated disease which comprises administering an effective cytokine-interferring amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In particular, compounds of formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy of any disease state in a human, or other mammal, which is exacerbated by or caused by excessive or unregulated IL-1, IL-6, IL-8 or TNF production by such mammal's cell, such as, but not limited to, monocytes and or macrophages.
Accordingly, in another aspect, this invention relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
There are many disease states in which excessive or unregulated IL- 1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resorption, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis. Recent evidence also links IL-1 activity to diabetes, pancreatic β cells and Alzheimer's disease.
In a further aspect, this invention relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof
Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, such as osteoporosis, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis and pyresis.
Compounds of formula (I) are also useful in the treatment of viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo. The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibiting-compounds of formula (1). Such viruses include, but are not limited to HIV-1, HIV-2 and HIV- 3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses, such as but not limited to, Herpes Zoster and Herpes Simplex. Accordingly, in a further aspect, this invention relates to a method of treating a mammal, preferably a human, afflicted with a human immunodeficiency virus (HIV) which comprises administering to such mammal an effective TNF inhibiting amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Compounds of formula (I) may also be used in association with the veterinary treatment of mammals, other than in humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to, the lentivirus infections such as equine infectious anaemia virus, caprine arthritis virus, visna virus, or the maedi virus, or the retroviruses, such as feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus.
The compounds of formula (I) may also be used topically in the treatment or prophylaxis of topical disease states mediated by or exacerbated by excessive cytokine production, such as by IL-1 or TNF respectively, such as inflamed joints, eczema, psoriasis and other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
Compounds of formula (I) have also been shown to inhibit the production of E -8 (Interleukin-8, NAP). Accordingly, in a further aspect, this invention relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease. These diseases are characterized by massive neutrophil infiltration such as, psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis. All of these diseases are associated with increased IL-8 production which is responsible for the chemotaxis of neutrophils into the inflammatory site. In contrast to other inflammatory cytokines (IL-1, TNF, and IL-6), IL-8 has the unique property of promoting neutrophil chemotaxis and activation. Therefore, the inhibition of IL-8 production would lead to a direct reduction in the neutophil infiltration.
The compounds of formula (I) are administered in an amount sufficient to inhibit cytokine, in particular IL-1, IL-8 or TNF, production such that it is regulated down to normal levels, or in some case to subnormal levels, so as to ameliorate or prevent the disease state. Abnormal levels of IL-1, IL-8 or TNF, for instance in the context of the present invention, constitute: (i) levels of free (not cell bound) IL-1, IL-8 or TNF greater than or equal to 1 picogram per ml; (ii) any cell associated IL-1, IL-8 or TNF; or (iii) the presence of IL-1, IL-8 or TNF mRNA above basal levels in cells or tissues in which IL-1, IL-8 or TNF, respectively, is produced.
The discovery that the compounds of formula (I) are inhibitors of cytokines, specifically IL-1, IL-8 and TNF is based upon the effects of the compounds of formulas (I) on the production of the IL-1, IL-8 and TNF in in vitro assays which are described herein. As used herein, the term "inhibiting the production of IL-1 (IL-8 or TNF)" refers to: a) a decrease of excessive in vivo levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal or sub-normal levels by inhibition of the in vivo release of the cytokine by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the genomic level, of excessive in vivo levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal or sub-normal levels; c) a down regulation, by inhibition of the direct synthesis of the cytokine (IL- 1, IL-8 or TNF) as a postranslational event; or d) a down regulation, at the translational level, of excessive in vivo levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal or sub-normal levels. As used herein, the term "TNF mediated disease or disease state" refers to any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disease stated mediated by TNF.
As used herein, the term "cytokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many other cells however also produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes and B-lymphocytes. Lymphokines are generally referred to as being produced by lymphoctye cells. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor- alpha (TNF- a) and Tumor Necrosis Factor beta (TNF-β).
As used herein, the term "cytokine interfering" or "cytokine suppresive amount" refers to an effective amount of a compound of formula (I) which will cause a decrease in the in vivo levels of the cytokine to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production. As used herein, the cytokine referred to in the phrase "inhibition of a cytokine, for use in the treatment of a HIV-infected human" is a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HIV gene expression and/or replication and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration. As TNF-β (also known as lymphotoxin) has close structural homology with
TNF-a (also known as cachectin) and since each induces similar biologic responses and binds to the same cellular receptor, both TNF-a and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise. A new member of the MAP kinase family, alternatively termed CSBP, p38, or
RK, has been identified independently by several laboratories recently [See Lee et al., Nature, Vol. 300 n(72), 739-746 (1994)]. Activation of this novel protein kinase via dual phosphorylation has been observed in different cell systems upon stimulation by a wide spectrum of stimuli, such as physicochemical stress and treatment with lipopolysaccharide or proinflammatory cytokines such as interleukin- 1 and tumor necrosis factor. The cytokine biosynthesis inhibitors, of the present invention, compounds of Formula (I), have been determined to be potent and selective inhibitors of CSBP/p38/RK kinase activity. These inhibitors are of aid in determining the signaling pathways involvement in inflammatory responses. In particular, for the first time a definitive signal transduction pathway can be prescribed to the action of lipopolysaccharide in cytokine production in macrophages. In addition to those diseases already noted herein, treatment of stroke, neurotrauma, cardiac and renal reperfusion injury, congestive heart failure, thrombosis, chronic renal failure, glomerulonephritis, angiogenesis & related processes, such as cancer, diabetes and pancreatic β cells diseases, multiple sclerosis, muscle degeneration, eczema, psoriasis, sunburn, and conjunctivitis are also included.
The cytokine inhibitors were subsequently tested in a number of animal models for anti-inflammatory activity. Model systems were chosen that were relatively insensitive to cyclooxygenase inhibitors in order to reveal the unique activities of cytokine suppressive agents. The inhibitors exhibited significant activity in many such in vivo studies. Most notable are its effectiveness in the collagen-induced arthritis model and inhibition of TNF production in the endotoxic shock model. In the latter study, the reduction in plasma level of TNF correlated with survival and protection from endotoxic shock related mortality. Also of great importance are the compounds effectiveness in inhibiting bone resorption in a rat fetal long bone organ culture system. Griswold et al., (1988) Arthritis Rheum. 31: 1406-1412; Badger, et al., (1989) Circ. Shock 27, 51-61; Votta et al., (1994)w vitro. Bone 15, 533-538; Lee et al., (1993). B Ann. N. Y. Acad. Sci. 696, 149-170.
Another aspect of the present invention is to the novel use of these CSBP/cytokine inhibitors for the treatment of chronic inflammatory or proliferative or angiogenic diseases which are caused by excessive, or inappropriate angiogenesis. Chronic diseases which have an inappropriate angiogenic component are various ocular neovasularizations, such as diabetic retinopathy and macular degeneration. Other chronic diseases which have an excessive or increased proliferation of vasculature are tumor growth and metastasis, atherosclerosis, and certain arthritic conditions. Therefore CSBP kinase inhibitors will be of utility in the blocking of the angiogenic component of these disease states. The term "excessive or increased proliferation of vasculature inappropriate angiogenesis" as used herein includes, but is not limited to, diseases which are characterized by hemangiomas and ocular diseases.
The term "inappropriate angiogenesis" as used herein includes, but is not limited to, diseases which are characterized by vesicle proliferation with accompanying tissue proliferation, such as occurs in cancer, metastasis, arthritis and atherosclerosis.
In order to use a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of formula (I) and a pharmaceutically acceptable carrier or diluent.
Compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of formula (I) may be administered in conventional dosage forms prepared by combining a compound of formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax. A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25mg. to about lg. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
Compounds of formula (I) may be administered topically, that is by non- systemic administration. This includes the application of a compound of formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation. Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan esteror a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 _C. for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol. Compounds of formua (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds of formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
For all methods of use disclosed herein for the compounds of formula (I), the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg/kg, more preferably from about 0.5 mg to 15mg. The daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg. The daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg kg to about 1 mg/kg per day. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
BIOLOGICAL EXAMPLES
The cytokine-inhibiting effects of compounds of the present invention were determined by the following in vitro assays: Interleukin - 1 (IL-1), Interleukin -8 (IL-8 ), and Tumour Necrosis Factor
(TNF) assays may be found in a number of publications, in particular suitable assays for use herein are described in Adams et al., US 5,593,992, whose disclosure is incorporated by reference.
In vivo TNF assay:
While the above indicated assay in an in vitro assay, the compounds of Formula (I) may also be tested in an in vivo system such as described in :
(1) Griswold et al., Drugs Under Exp. and Clinical Res..XIX (6). 243-48 (1993); or
(2) Boehm, et al., Journal Of Medicinal Chemistry 39, 3929-3937 (1996) whose disclosures are incorporated by reference herein in their entirety.
LPS-induced TNFα Production in Mice and Rats
In order to evaluate in vivo inhibition of LPS-induced TNFα production in rodents, both mice and rats are injected with LPS. Mouse Method
Male Balb/c mice from Charles River Laboratories are pretreated (30 minutes) with compound or vehicle. After the 30 min. pretreat time, the mice are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma
Chemical Co., St Louis, MO) 25 ug/mouse in 25 ul phosphate buffered saline (pH 7.0) intraperitoneally. Two hours later the mice are killed by CO2 inhalation and blood samples are collected by exsanguination into heparinized blood collection tubes and stored on ice. The blood samples are centrifuged and the plasma collected and stored at -20°C until assayed for TNFα by ELIS A. Rat Method
Male Lewis rats from Charles River Laboratories are pretreated at various times with compound or vehicle. After a determined pretreat time, the rats are given
LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO) 3.0 mg kg intraperitoneally. The rats are killed by CO2 inhalation and heparinized whole blood is collected from each rat by cardiac puncture 90 minutes after the LPS injection. The blood samples are centrifuged and the plasma collected for analysis by ELISA for TNFα levels.
ELISA Method
TNFα levels were measured using a sandwich ELISA, as described in Olivera et al., Circ. Shock, 37, 301-306, (1992), whose disclosure is incorporated by reference in its entirety herein, using a hamster monoclonal antimurine TNFα (Genzyme, Boston, MA) as the capture antibody and a polyclonal rabbit antimurine TNFa (Genzyme) as the second antibody. For detection, a peroxidase-conjugated goat antirabbit antibody (Pierce, Rockford, IL) was added, followed by a substrate for peroxidase (1 mg/ml orthophenylenediamine with 1% urea peroxide). TNFα levels in the plasma samples from each animal were calculated from a standard curve generated with recombinant murine TNFα (Genzyme).
LPS-Stimulated Cytokine Production In Human Whole Blood
Assay: Test compound concentrations were prepared at 10 X concentrations and
LPS prepared at 1 ug/ml (final cone, of 50 ng/ml LPS) and added in 50 uL volumes to 1.5 mL eppendorf tubes. Heparinized human whole blood was obtained from healthy volunteers and was dispensed into eppendorf tubes containing compounds and LPS in 0.4 mL volumes and the tubes incubated at 37 C. Following a 4 hour incubation, the tubes were centrifuged at 5000 rpm for 5 minutes in a TOMY microfuge, plasma was withdrawn and frozen at -80 C.
Cytokine measurement: IL-I and/or TNF were quantified using a standardized ELISA technology. An in-house ELISA kit was used to detect human IL-1 and TNF. Concentrations of IL-1 or TNF were determined from standard curves of the appropriate cytokine and IC50 values for test compound (concentration that inhibited 50% of LPS-stimulated cytokine production) were calculated by linear regression analysis. CSBP Kinase Assay:
This assay measures the CSBP-catalyzed transfer of 32p frθm [a-32p]ATP to threonine residue in an epidermal growth factor receptor (EGFR)-derived peptide (T669) with the following sequence: KRELVEPL7PSGEAPNQALLR (residues 661-681). (See Gallagher et al., "Regulation of Stress Induced Cytokine Production by Pyridinyl Imidazoles: Inhibition of CSPB Kinase", BioOrganic & Medicinal Chemistry, to be published 1996).
Kinase reactions (total volume 30 ul) contain: 25 mM Hepes buffer, pH 7.5; 10 mM MgCl2; 170 uM ATPO); 10 uM Na ortho vanadate; 0.4 mM T669 peptide; and 20-80 ng of yeast-expressed purified CSBP2 (see Lee et al., Nature 300, n(72),
739-746 (Dec. 1994)). Compounds (5 ul from [6X] stock(2)) are pre-incubated with the enzyme and peptide for 20 min on ice prior to starting the reactions with
32P/MgATP. Reactions are incubated at 30 °C for 10 min and stopped by adding 10 ul of 0.3 M phosphoric acid. 32P-labeled peptide is separated on phosphocellulose (Wattman, p81) filters by spotting 30 ul reaction mixture. Filters are washed 3 times with 75 mM phosphoric acid followed by 2 washes with H2O, and counted for 32P.
(!) The Km of CSBP for ATP was determined to be 170 uM. Therefore, compounds screened at the Km value of ATP.
(2) Compounds are usually dissolved in DMSO and are diluted in 25 mM Hepes buffer to get final concentration of DMSO of 0.17%.
Representative compounds of Formula (I), Examples 1 to 6 have all demonstrated positive inhibitory activity of an IC50 of < 50uM in this binding assay.
Prostoglandin endoperoxide synthase-2 (PGHS-2) assay: This assay describes a method for determining the inhibitory effects of compounds of Formula (I) on human PGHS-2 protein expression in LPS stimulated human monocytes. A suitable assay for PGHS-2 protein expression may be found in a number of publications, including US Patent 5,593,992 whose disclosure is incorporated herein by reference.
TNF-a in Traumatic Brain Injury Assay
This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats. Since TNF- a is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- a plays an important role in both the acute and regenerative response to CNS trauma. A suitable assay may be found in WO 97/35856 whose disclosure is incorporated herein by reference.
CNS Injury model for IL-b mRNA
This assay characterizes the regional expression of interleukin- lβ (IL-lβ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-lβ mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-lβ play a role in the post- traumatic pathologic or regenerative sequelae of brain injury. A suitable assay may be found in WO 97/35856 whose disclosure is incorporated herein by reference. Angiogenesis Assay:
Described in WO 97/32583, whose disclosrue is incorporated herein by reference, is an assay for determination of inflammatory angiogenesis which may be used to show that cytokine inhibition will stop the tissue destruction of excessive or inappropriate proliferation of blood vessels.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims

What is claimed is
1. A compound of formula (I):
Figure imgf000044_0001
wherein:
Rl is 4-pyrimidinyl ring which ring is substituted by Y, or NHRa, and is optionally substituted independently one to three times with Y, NHRa, optionally substituted Ci-4 alkyl, halogen, hydroxyl, optionally substituted Ci-4 alkoxy, optionally substituted Cι_4 alkylthio, optionally substituted Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(Rιo)C(O)Rb,
N(Rιo)S(O)2Rd» or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or
NR15; Y is Xι-Ra; Xi is sulfur or oxygen;
Ra is Cι_6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylC 1 -6 alkyl, heteroaryl, or heteroarylCi-6alkyl, wherein each of these moieties may be optionally substituted; Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylC 1.4 alkyl; Rd is Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylC 1.4 alkyl; R2 is hydrogen, Ci-io alkyl, halo- substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkylCi-ioalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, heterocyclyl, heterocyclylC 1-10 alkyl, (CRioR28)n OR12, (CRιoR28)n'ORl3, (CRioR28)n'
S(O)mR25, (CRlθR28)n S(O)2R25- (CRi0R28)n'NHS(O)2R25,
(CRιoR28)n'NR8R9, (CRlθR28)n'Nθ2, (CRιoR28)n'CN, ,
(CRι0R28)n'S(O)mNR8R9, (CRioR28)n'C(Z)Rι3, (CRι0R28)n'C(Z)ORι3,
(CRι0R28)n'C(Z)NR8R9, (CRι0R28)n'C(Z)NRι3ORi2, (CRιoR28)n'NRlθC(Z)Ri3, (CRιoR28)n'NRlθC(Z)NR8R9,
(CRι0R28)n'N(OR2l)C(Z)NR8R9, (CRιoR28)n'N(OR2l)C(Z)Ri3,
Figure imgf000044_0002
(CRlθR28)n'NRlθC(=NR27)NR8R9,
(CRι0R28)n'OC(Z)NR8R9, (CRιoR28)n'NRlθC(Z)ORιo, (CRioR28)n'NRlθC(Z)ORιo, 5-(R25)- ,4-oxadizaol-3-yl or 4-(Rι2)-5- (Rl8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl;wherein the cyclcoalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl moieties may be optionally substituted; n is 0 or an integer from 1 to 10; n' is an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; t is a number having a value of 1 , 2 or 3; v is 0, or an integer having a value of 1 or 2; R3 is Q-(YDt ;
Q is an aryl or heteroaryl group; Z is oxygen or sulfur; Yi is independently selected from hydrogen, Ci-5 alkyl, halo-substituted Ci-5 alkyl, halogen, or (CRιoR2θ)nY2; Y2 is OR8, NO2, S(O)m"Rl l, SR8, S(O)m"OR8, S(O)mNR8R9, NR8R9,
O(CRioR20)n'NR8R9. C(O)R8, CO2R8, CO2(CRioR20)n' CONR8R9, ZC(O)R8, CN, C(Z)NR8R9, NRiθC(Z)R8, C(Z)NR8OR9, NRioC(Z)NR8R9, NRioS(O)m »Ri 1, N(OR2l)C(Z)NR8R9, N(OR2l)C(Z)R8, C(=NOR2l)R8,
NRioC(=NRi5)SRn, NRι0C(=NRι5)NR8R9, NRιoC(=CRi4R24)SRl l, NRioC(=CRi4R24)NR8R9. NRιoC(O)C(O)NR8R9, NRιoC(O)C(O)ORio, C(=NRi3)NR8R9, C(=NORi3)NR8R9, C(=NRι3)ZRπ, OC(Z)NR8R9, NRioS(O)m"CF3, NRioC(Z)ORio, 5-(Rι8)-l,2,4-oxadizaol-3-yl or 4-(R 12)-5-(R 18R 19)-4,5-dihydro- 1 ,2,4-oxadiazol-3-yl ;
R4 is phenyl, naphth-1-yl or naphth-2-yl which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4- phenyl, 4-naphth-l-yl or 5-naphth-2-yl substituent, is halo,nitro, cyano, C(Z)NR7Ri7, C(Z)OR23, (CRιoR2θ)vCOR36, SR5, SOR5, OR36, halo- substituted-Ci-4 alkyl, C1-4 alkyl, ZC(Z)R36, NRιoC(Z)R23, or
(CRioR2θ)vNRlθR20 and which, for other positions of substitution, is halo, nitro, cyano, C(Z)NRiόR26, C(Z)OR8, (CRιoR2θ)m"COR8, S(O)mR8, OR8, halo-substituted-Ci-4 alkyl, C1-.4 alkyl, CRioR2θ)m"NRlθC(Z)R8, NRlθS(O)m'Rι 1, NRiθS(O)m'NR7Rl7, ZC(Z)R8 or (CRι0R20)m"NRl6R26; R5 is hydrogen, Cι_4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH; R7 and R17 is each independently selected from hydrogen or Cι_4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR22; R is hydrogen, heterocyclyl, heterocyclylalkyl or Ri 1 ;
R9 is hydrogen, Cμio alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl or R8 and R9 may together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12;
RlO and R20 is each independently selected from hydrogen or Cι_4 alkyl;
Rl l is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;
Rl2 is hydrogen, C(Z)Ri3 or optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted arylCj-4 alkyl, or S(O)2R25;
Rl3 is hydrogen, Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclylC i- 10 alkyl, aryl, arylCi-io alkyl, heteroaryl or heteroaryl Ci-io alkyl, wherein all of these moieties may be optionally substituted; Rl4 and R24 is each independently selected from hydrogen, alkyl, nitro or cyano; Rl5 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl or aryl;
Rl6 and R26 is each independently selected from hydrogen or optionally substituted Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12 ;
Rl8 and R19 is each independently selected from hydrogen, Ci-4 alkyl, substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl or together denote a oxygen or sulfur; R21 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, aryl Ci-4 alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, aroyl, or Ci-io alkanoyl ; R22 is RlO or C(Z)-Ci-4 alkyl;
R23 is C 1-4 alkyl, halo-substituted-Ci-4 alkyl, or C3-5 cycloalkyl; R36 is hydrogen or R23; R25 is Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, arylalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroarylalkyl; R27 is hydrogen, cyano, Ci-4 alkyl, C3_7 cycloalkyl, or aryl;
R28 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylC 1 -4 alkyl moiety, all of which may be optionally substituted; or a pharmaceutically acceptable salt thereof.
2. The compound according to Claim 1 wherein Ri is a 4-pyrimidinyl group substituted by Y.
3. The compound according to Claim 2 wherein Xi is oxygen, and Ra is an optionally substituted aryl or an optionally substituted arylalkyl.
4. The compound according to Claim 2 wherein Ra is optionally substituted C .4 alkyl.
5. The compound according to Claim 1 wherein R2 is hydrogen, optionally substituted Ci-io alkyl group, an optionally substituted aryl, an optionally substituted heterocyclyl, or an optionally substituted heterocyclylCi-io alkyl.
6. The compound according to Claim 1 wherein Q is an optionally substitued phenyl.
7. The compound according to Claim 6 wherein Q is phenyl substitued halogen, halosubstituted alkyl, or (CRιoR2θ)nY2 and Y2 is OR8, S(O) 'Rl 1. SR8, S(O)mNR8R9, or NR8R9.
8. The compound according to Claim 1 wherein R4 is optionally substituted phenyl, naphth-1-yl or naphth-2-yl wherein the 4-phenyl, 4-naphth-l-yl or 5-naphth- 2-yl moiety are substituted by one or two substituents each independently selected from halogen, SR5, SOR5, OR36, or (CRιoR2θ) NRlθR20- and for other positions of substitution on these rings the substitution is halogen, S(O)mR8, OR8, (CRioR20)mNRl6R26, NRι0C(Z)R8 and NRι0S(O)mRl 1-
9. The compound according to 8 wherein the substituent in the 4-position for phenyl and naphth-1-yl and on the 5-position in naphth-2-yl is fluoro, chloro, SR5 or SOR5.
10. The compound of formula (I), according to Claim 1 , which is: 2-[(4-N,N-Dimethyl)aminomethylphenyl]-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyridminyl)imidazole (+/-) 2-(4-Methylsulfinylphenyl]-4-(4-fluorophenyl)-5-(2-phenoxy-4- pyridminyl)imidazole
2-(4-Methylthiophenyl]-4-(4-fluorophenyl)-5-(2-phenoxy-4-pyridminyl)imidazole; or a pharmaceutically acceptable salt thereof.
11. The compound of formula (I), according to Claim 1 , which is: 2-(4-Methylthiophenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)imidazole 2-(4-Methylsulfinylphenyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole 2-[(4-N,N-Dimethyl)aminomethylphenyl]-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole ; or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising an effective amount of a compound according to any of Claims 1 to 11, and a pharmaceutically acceptable carrier or diluent.
13. A method of prophylaxis, or the treatment of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound of Formula (I) according to Claim 1.
14. The method according to Claim 13 wherein the mammal is afflicted with a CSBP/RK/p38 kinase mediated disease which is psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, congestive heart failure, chronic renal failure, glomerulonephritis, angiogenesis & related processes, thrombosis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermititis, psoriasis, sunburn, or conjunctivitis.
PCT/US1998/012828 1997-06-19 1998-06-19 Novel aryloxy substituted pyrimidine imidazole compounds Ceased WO1998057966A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP50486599A JP2002505690A (en) 1997-06-19 1998-06-19 Novel aryloxypyrimidine-substituted imidazole compounds
CA002294137A CA2294137A1 (en) 1997-06-19 1998-06-19 Novel aryloxy substituted pyrimidine imidazole compounds
AU81549/98A AU8154998A (en) 1997-06-19 1998-06-19 Novel aryloxy substituted pyrimidine imidazole compounds
EP98931409A EP0994870A4 (en) 1997-06-19 1998-06-19 Novel aryloxy substituted pyrimidine imidazole compounds
US09/445,652 US6610695B1 (en) 1997-06-19 1998-06-19 Aryloxy substituted pyrimidine imidazole compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5022497P 1997-06-19 1997-06-19
US60/050,224 1997-06-19

Publications (1)

Publication Number Publication Date
WO1998057966A1 true WO1998057966A1 (en) 1998-12-23

Family

ID=21964046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/012828 Ceased WO1998057966A1 (en) 1997-06-19 1998-06-19 Novel aryloxy substituted pyrimidine imidazole compounds

Country Status (6)

Country Link
US (1) US6610695B1 (en)
EP (1) EP0994870A4 (en)
JP (1) JP2002505690A (en)
AU (1) AU8154998A (en)
CA (1) CA2294137A1 (en)
WO (1) WO1998057966A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300347B1 (en) 1997-06-30 2001-10-09 Novartis Ag 2-substituted 4,5-diaryl imidazoles
EP1080087A4 (en) * 1998-05-22 2001-11-21 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US6362193B1 (en) 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US6503930B1 (en) 1997-05-22 2003-01-07 G.D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
EP1119254A4 (en) * 1998-10-07 2004-05-12 Smithkline Beecham Corp Novel treatment for stroke management
US6774127B2 (en) 1997-06-13 2004-08-10 Smithkline Beecham Corporation Pyrazole and pyrazoline substituted compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6861417B2 (en) 1998-11-04 2005-03-01 Smithkline Beecham Corporation Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US7053099B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
EP1676574A2 (en) 2004-12-30 2006-07-05 Johnson &amp; Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
WO2007049820A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
US7223760B2 (en) 1998-08-20 2007-05-29 Smithkline Beecham Corporation Substituted triazole compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US7320996B2 (en) 2001-08-15 2008-01-22 Sugen, Inc Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer
US7612094B2 (en) 2002-04-04 2009-11-03 Biogen Idec Ma Inc. Tri-substituted heteroaryls and methods of making and using the same
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100436450C (en) * 2003-10-16 2008-11-26 霍夫曼-拉罗奇有限公司 Triaryl imidazole
US7144889B2 (en) * 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) * 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
EA011242B1 (en) * 2004-03-25 2009-02-27 Янссен Фармацевтика Н.В. Imidazole compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5686455A (en) * 1992-01-13 1997-11-11 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
GR75287B (en) 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
IE914327A1 (en) 1990-12-13 1992-06-17 Smithkline Beecham Corp Novel csaids
JPH06504779A (en) 1990-12-13 1994-06-02 スミスクライン・ビーチャム・コーポレイション New CSAIDS
US6008235A (en) 1992-01-13 1999-12-28 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US5716972A (en) 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
PT724588E (en) 1993-09-17 2000-05-31 Smithkline Beecham Corp PROTEIN FROM LIGACAO TO DRUGS
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
JPH09505055A (en) 1993-11-08 1997-05-20 スミスクライン・ビーチャム・コーポレイション Oxazole for treatment of cytokine-mediated diseases
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
FI972970A7 (en) 1995-01-12 1997-09-11 Smithkline Beecham Corp New compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
PL184819B1 (en) 1995-10-06 2002-12-31 Merck & Co Inc Substituted imidazoles
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
WO1997025047A1 (en) 1996-01-11 1997-07-17 Smithkline Beecham Corporation Novel cycloalkyl substituded imidazoles
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
PL187516B1 (en) 1996-01-11 2004-07-30 Smithkline Beecham Corp Novel substituted derivatives of imidazole
WO1997032583A1 (en) 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
JP2000507558A (en) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Novel treatment for CNS injury
US6235760B1 (en) 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
EP0906307B1 (en) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
WO1998016230A1 (en) 1996-10-17 1998-04-23 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5929076A (en) 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
RU2222534C2 (en) 1997-04-24 2004-01-27 Орто-Макнейл Фармасьютикал, Инк. Substituted imidazoles, method for their preparing, pharmaceutical composition based on thereof, methods for treatment of cytokine-mediated diseases
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
AR016294A1 (en) 1997-07-02 2001-07-04 Smithkline Beecham Corp IMIDAZOL SUBSTITUTE COMPOSITE, PHARMACEUTICAL COMPOSITION CONTAINING IT, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR SUPREPARATION
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
EP1021173A1 (en) 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
CN1548436A (en) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ Novel 2-alkyl substituted imidazole compounds
WO1999061440A1 (en) 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686455A (en) * 1992-01-13 1997-11-11 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0994870A4 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6852740B2 (en) 1997-05-22 2005-02-08 G. D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US7153959B2 (en) 1997-05-22 2006-12-26 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6617324B1 (en) 1997-05-22 2003-09-09 G. D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6503930B1 (en) 1997-05-22 2003-01-07 G.D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6774127B2 (en) 1997-06-13 2004-08-10 Smithkline Beecham Corporation Pyrazole and pyrazoline substituted compounds
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
US6300347B1 (en) 1997-06-30 2001-10-09 Novartis Ag 2-substituted 4,5-diaryl imidazoles
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6362193B1 (en) 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
EP1080087A4 (en) * 1998-05-22 2001-11-21 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US6548520B1 (en) 1998-05-22 2003-04-15 Smithkline Beecham Corporation Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US7223760B2 (en) 1998-08-20 2007-05-29 Smithkline Beecham Corporation Substituted triazole compounds
EP1119254A4 (en) * 1998-10-07 2004-05-12 Smithkline Beecham Corp Novel treatment for stroke management
US6861417B2 (en) 1998-11-04 2005-03-01 Smithkline Beecham Corporation Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines
US6525059B1 (en) 1998-11-20 2003-02-25 G. D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053099B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7320996B2 (en) 2001-08-15 2008-01-22 Sugen, Inc Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer
US7612094B2 (en) 2002-04-04 2009-11-03 Biogen Idec Ma Inc. Tri-substituted heteroaryls and methods of making and using the same
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
EP1676574A2 (en) 2004-12-30 2006-07-05 Johnson &amp; Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
WO2007049820A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4

Also Published As

Publication number Publication date
AU8154998A (en) 1999-01-04
EP0994870A1 (en) 2000-04-26
EP0994870A4 (en) 2002-10-23
JP2002505690A (en) 2002-02-19
US6610695B1 (en) 2003-08-26
CA2294137A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
US6610695B1 (en) Aryloxy substituted pyrimidine imidazole compounds
AU760527C (en) Novel 2-alkyl substituted imidazole compounds
US6599910B1 (en) Substituted triazole compounds
US6774127B2 (en) Pyrazole and pyrazoline substituted compounds
US6362193B1 (en) Cycloalkenyl substituted compounds
US6861417B2 (en) Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines
US6335340B1 (en) compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
US6469018B1 (en) Compounds
WO1999001136A1 (en) Novel substituted imidazole compounds
WO1999001130A1 (en) Novel substituted imidazole compounds
AU737637C (en) Novel substituted imidazole compounds
NZ520906A (en) 2(alkyl)-, 5(4-pyrimidinyl)- substituted imidazole derivatives and pharmaceuticals thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CZ EE GE HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2294137

Country of ref document: CA

Ref country code: CA

Ref document number: 2294137

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998931409

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09445652

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998931409

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998931409

Country of ref document: EP